



For personal use only

Annual Report 2024

Contents

Who is Vita Life Sciences? 2
Chairman's Letter 4
Group Financial Metrics 5
Managing Director's Review 6
Directors' Report 9
Auditor's Independence Declaration 21
Consolidated Statement of Comprehensive Income 24
Consolidated Statement of Financial Position 25
Consolidated Statement of Cash Flows 26
Consolidated Statement of Changes in Equity 27
Notes to the Financial Statements 29
Directors' Declaration 68
Independent Audit Report 69
ASX Additional Information 73
Corporate Directory 75



Who is VitaLife Sciences?

For personal use only



Vita Life Sciences Limited (“Vita Life Sciences”, “the Company” or “the Group”) is a multinational healthcare Company involved in formulating, packaging, sales and distribution of vitamins and supplements. Vita Life Sciences is represented by two major brands of high quality supplements throughout the Asia-Pacific region, Vita Health and Herbs of Gold.



Vita Life Sciences has a Company-wide commitment to:

- Focus its efforts on the health and well-being of customers;
- Conduct activities in a socially responsible manner;
- Create a conducive working and rewarding environment for its employees; and
- Provide competitive returns on our shareholders' investments.

Our History

Vita Health commenced business as a retail pharmacy in Singapore in 1947. In 1973, it launched its own brand of vitamins and supplements with flagship products that included Supa Formula Three and Crowning Glory. Engaging in a philosophy to “think internationally but act locally”, Vita Health has developed products that are consistent with global trends while adapting the formulation and product needs of local markets in compliance with the respective countries drug control authorities. Noting the potential to increase its resources to generate growth in research, marketing and product development, Vita Life Sciences purchased Vita Health, including the Malaysian and Singaporean businesses, in 2000.

Herbs of Gold was founded in Australia in 1989 and soon became known and trusted for its integrity and reliability by health food retailers and consumers alike. Herbs of Gold was acquired by Vita Life Sciences in 2001. Subsequently, Vita Life Sciences has expanded its operations and continues to operate in Vietnam, China and Indonesia.

Our Future

Vita Life Sciences has grown from strength to strength and is now a significant healthcare company with circa 350 registered products throughout Australia and Asia. Vita Life Sciences strategy is to establish a sustainable platform for revenue growth through expanding operations into new markets within Asia.

Our People

Besides a strong and experienced management team, the talent of Vita Life Sciences people is regarded as the determining factor in the success of the Company. There is a culture of fostering leadership, individual accountability and teamwork. Vita Life Sciences employees are professionals whose entrepreneurial behaviour is result-oriented and guided by personal integrity. They strive for the success of their own departments in the interests of Vita Life Sciences as a global company and Vita Life Sciences attributes its achievement and success to their dedication.

Chairman's Letter

Dear Shareholders,

The geographic diversification of the Company's business with well-established operations in 4 markets, Australia, Malaysia, China and Singapore has stood it in good stead for many years including 2024. These core markets continue to offer significant opportunities for growth as we expand product range and reach and solidify the Group's position as a leading provider of nutritional solutions.

The Group in 2024 benefitted from strong financial results in Australia and Malaysia, a solid result in Singapore whilst China sales and profit contribution was less in 2024 than 2023. The overall financial performance was reasonable with sales up 8.3% to \$79.3m and profit before tax flat at \$12.6m.

In the 2nd half of 2024 Directors took the decision to reset the China business, short term pain for longer term gain. The reset was largely completed in 2024, however, it is likely it will take some time to regain sales momentum previously achieved. The geographic diversification of our business meant the reset could be achieved without adversely impacting overall financial performance.

Strategic expansion

As part of an ongoing strategy to expand market presence the Company is focussing on developing its business units in Vietnam, Indonesia and China. Whilst these business units are at different stages of development, all present strong growth opportunities, driven by rising consumer demand for health and wellness products. The regions allow us to leverage our expertise and trusted brands, while introducing new and innovative products tailored to local consumer needs.

To do this requires substantial investment and as previously advised to Shareholders the Group has begun to increase its investment when compared to previous years. Increasing investment reduces profit from what it may have otherwise been but in the medium to longer term the Company will benefit from increased geographic diversification, sales and profitability.

Commitment to quality

Product quality and sustainability remain at the heart of Group operations. The global demand for clean, effective, and ethically produced health supplements continues to rise, and Vita Life Sciences is committed to meeting these needs. We will continue to invest in sustainable sourcing and responsible production processes, ensuring that our products contribute to the well-being of our customers.

Through continuous product innovation and rigorous testing, we remain focused on providing superior health solutions that are safe, effective, and aligned with the needs of today's health-conscious consumers.

Financial health and dividend

The Company had no borrowings, a cash balance of \$28.6m, up 16.1% and net assets of \$52.3m, up 20.6% at December 2024.


The Company's dividend for FY 2024 is 10.0 cents per share fully franked (3.5 cents interim and 6.5 cents final), the 15th consecutive year of dividend payments to Shareholders. The 10.0 cents per share dividend equates to a 63% dividend to profit after tax ratio and is in line with Directors' dividend policy.

Looking Ahead

As we look to the future, we are optimistic about the opportunities ahead. Our diverse and expanding portfolio, combined with a strong presence in key international markets, positions us well for continued growth. The health and wellness industry is evolving rapidly, and Vita Life Sciences is well-placed to capture these opportunities with our innovative products, solid brand reputation, and strategic expansion.

The Board thanks the Company's dedicated management team and employees for their unwavering commitment, hard work, and passion. Their efforts are the foundation of our success.

Finally, I would like to express my gratitude to Shareholders for your continued trust and support. We look forward to another successful year as we work together to achieve new heights.



Henry Townsing
Chairman
24 March 2025

Group Financial Metrics

Sales Revenue
\$79.5m
up 8.3% on FY 2023

Profit before
Taxation:
\$12.6m
up 1.5% on FY 2023

Earnings Per Share:
15.8 cents
down 6.7% on FY 2023

Net Profit after
Taxation:
\$8.8m
down 3.3% on FY 2023

Net Cash Balance:
\$28.6m
up 16.1% on FY 2023

Total Dividend
Distribution
Per Share:
10.0 cents
up 11.1% on FY 2023

Total Equity:
\$52.3m
up 20.6% on FY 2023

For personal use only

Managing Director's Review



Dear Shareholders,

I'm pleased to present the financial performance and operational highlights for the financial year 2024. The Company has delivered a consistent performance, reflecting both growth in key markets and continued strategic investments aimed at expanding our brand presence and footprint.

The Group achieved record revenue of \$79.5 million, an increase of 8.3% compared to PCP. Profit before tax (PBT) rose by 1.5% to \$12.6 million, reflecting our ability to attract new retail partners and expand product consumption across markets. The health and well being of consumers remains a major motivational factor when it comes to the consumption of vitamins and supplements. The Group is very well positioned to leverage this through a strong pipeline of new products and innovative products.

Another significant part of this success is due to our increased investment in marketing and retailer support throughout the year, reinforcing our commitment to brand growth and market penetration. This approach is aligned with our strategic goal of enhancing brand awareness while sustaining long-term revenue growth. Despite the challenging global macroeconomic environment, we experienced positive trading conditions, which highlighted the resilience of our strategy and market positioning.

The Australian business achieved a record revenue of \$44.4 million, up 4% on PCP. EBIT was \$6.7 million, reflecting a 7% increase compared to the previous period.

The Australian business achieved a record revenue of \$44.4 million, up 4% on PCP. EBIT was \$6.7 million, reflecting a 7% increase compared to the previous period. Domestic channels, including Health Food, Pharmacy, and Daigou, delivered strong performance with an 18% growth, driven by consumer demand and an expanded pharmacy network. However, direct export sales to China saw a decline, primarily due to the weakening of traditional e-commerce platforms and consumption patterns in the region. This also coincided with our decision to reduce inventory supply to China in the second half of FY 2024. In response to the evolving markets in China, a decision was made not to extend the contract of the distributor beyond 2024. The Company has now formalised a new distribution partnership with Ruo Yu Chen (RYC). RYC is a prominent health and wellness company and a leading e-commerce trader working with over 100 brands worldwide.

The Malaysian business achieved a record revenue of \$25.7 million, marking a 12% increase on the PCP, with EBIT growing by 9% to \$6.3 million. The Malaysian market remains robust, driven by higher consumer demand for VitaHealth products. The performance of this market continues to demonstrate resilience, even amidst competitive and economic pressures. We also saw strong momentum from a solid pipeline of new product launches and successful local marketing initiatives.

In Singapore, revenue grew by 21%, reaching \$7.6 million. The Singapore market saw improvements in revenue contributions from traditional selling channels, supported by intensified branding efforts across the region.

Revenue from our other Asian markets, including Vietnam and Indonesia, increased by 15% to \$1.8 million, driven by marginal growth in Vietnam, especially from the launch of Herbs of Gold across the ConCung network of stores.

The Group has delivered another year of revenue growth, supported by strategic investments and resilience in a competitive market environment. We are confident in our continued success and remain focused on driving further growth across all regions. I would like to take this opportunity to thank all the dedicated staff for their continued dedication and commitment to the organisation. Management looks forward to updating you on our progress as we move through 2025.

Andrew O'Keefe



Managing Director
24 March 2025

For personal use only

Directors' Report



YOUR DIRECTORS SUBMIT THEIR REPORT FOR THE YEAR ENDED 31 DECEMBER 2024

DIRECTORS

The names and details of the Company's Directors in office during the financial year and until the date of this report are as follows. Directors were in office for this entire period unless otherwise stated.

Names, qualifications, experience and special responsibilities

Mr Henry G Townsing

Chairman

Non-Executive Director

Dip Val

Mr Townsing was appointed as the Chairman of the Company effective 28 May 2021 (was Acting Chairman since 13 October 2016).

Mr Townsing brings over 30 years' experience in corporate finance and private equity. He was a Director of the Company, from 1985 to 1992, 2004 to 2009 and was reappointed a Director on 22 December 2011.

Mr Townsing resides in Melbourne.

Mr Andrew O'Keefe

Managing Director

Dip. Mkt Mgt

Mr O'Keefe was appointed Managing Director of the Company on 1 January 2017.

Mr O'Keefe has over 20 years' experience within the Australian pharmaceutical and healthcare industry. During his career Mr O'Keefe has held senior leadership positions in publicly listed companies and in recent times was the CEO of Australia's largest Heath Food distributor and retailer. Andrew O'Keefe was appointed to the position of Chief Executive Officer – Herbs of Gold Australia in Oct 2014.

Mr O'Keefe resides in Sydney.

Mr Peter Osborne

Non-Executive Director

B Sc, Pg Dip Mkt

Mr Osborne was appointed as a Non-Executive Director of the Company on 1 August 2023.

Mr. Osborne has extensive experience in business development, sales and marketing, trade development, export and investment facilitation and promotion. He served as Australian Senior Trade Commissioner in Beijing, Shanghai, Hong Kong and Taiwan over 20-years prior to becoming Managing Director Asia for Blackmores Ltd in 2009 - 2020.

He is also a non-executive director of Nutritional Growth Solutions Ltd (ASX: NGS), director of Advangen (Japan), strategic advisor to Edison Partners, advisor to Daiken Biomedical (Taiwan) and external advisor to Bain & Company.

Mr Osborne resides in Taipei, Taiwan.

Mr Jack Teoh

Non-Executive Director

B Com

Mr Teoh was appointed as a Non-Executive Director of the Company on 30 September 2022.

Mr. Teoh is a businessman involved in a range of private companies, with particular experience in finance and technology. He was also a director of Tuas Limited from July 2020 till August 2022, and Total Forms Pty Ltd, a private Australian software business. Mr. Jack Teoh is also on the Board of TPG Telecom as a non-executive director since March 2021.

Mr Teoh resides in Sydney.

Mr Chin L Khoo

Company Secretary

Chief Financial Officer

CA, CPA, AGIA, MBA

Mr Khoo was appointed the Chief Financial Officer of the Company effective 1 May 2017 and the Company Secretary effective 30 June 2017. Mr Khoo had previously held the Company Secretary position briefly in 2011.

Mr Khoo has spent over the past 30 years working in various industries in the Asia Pacific region. He was also with the Group from 2004 to 2011.

Mr Khoo resides in Sydney.

INTERESTS IN THE SHARES OF THE COMPANY AND RELATED BODIES CORPORATE

The following table sets out each Director's relevant interest in shares of the Company as at the date of this report.

Directors		Shareholdings as at Directors' report date
Mr Andrew O'Keefe	BI	890,000
Mr Peter Osborne	BI	30,094
Mr Henry G Townsing	BI	15,270
Mr Henry G Townsing	NBI	494,744

BI: Beneficial Interest

NBI: Non-beneficial interest

DIVIDENDS

On 24 February 2025, the Directors announced a final fully franked dividend of 6.50 cents per share totalling \$3,619,563 in respect of the financial year ended 31 December 2024 (2023: fully franked dividend of 6.00 cents per share totalling \$3,231,008), payable on 11 April 2025. A fully franked interim dividend of 3.50 cents per share was paid on 4 October 2024 (2023: fully franked interim dividend of 3.00 cents per share).

PRINCIPAL ACTIVITIES

The principal activities of the Group in the course of the financial year consisted of formulating, packaging, sales and distribution of vitamins and supplements.

REVIEW OF OPERATIONS AND FINANCIAL RESULTS

Refer to Managing Director's Review.

SIGNIFICANT CHANGES IN STATE OF AFFAIRS

Share Buy-Back

On 22 May 2024, the Company announced an on-market share buy-back of up to 15% of the Company's shares on issue funded from the Group's existing cash reserves. During the financial year ended 31 December 2024, the Company bought back 714,555 (2023: 126,475) shares for total consideration of \$1,392,592 (2023: \$208,421).

SIGNIFICANT EVENTS AFTER BALANCE DATE

Dividends

On 24 February 2025, the Directors announced a final fully franked dividend of 6.50 cents per share totalling \$3,619,563 in respect of the financial year ended 31 December 2024 (2023: fully franked dividend of 6.00 cents per share totalling \$3,231,008), payable on 12 April 2025. A fully franked interim dividend of 3.50 cents per share was paid on 4 October 2024 (2023: fully franked interim dividend of 3.00 cents per share).

A new office lease agreement was entered into by Herbs of Gold Pty Ltd for a period of 5 years, prior to 31 December 2024 but effective from May 2025. The asset and liability for this lease was not recorded in the books at of 31 December 2024 due to various conditions precedent.

Other than the above matters, there are no subsequent events after balance date that affect the operating results or financial position of the Company and its subsidiaries in future financial periods.

FUTURE DEVELOPMENTS AND RISKS

The Board has continued confidence in the Company's strategies, in the capability of the management team and in the strength of the brands within the Group and, are committed to growing the business and delivering improved shareholder returns in the coming year.

In this regard, the Group plans to continue increasing investment in both advertising and promotional activities, whilst broadening distribution channels within and beyond key markets. This strategy may impact profitability in the short term, with a view to increase profitability in the medium term.

The Company is also wary of the potential challenges ahead including the ongoing need to satisfy consumers, discounting by competitors and maintaining high quality standards while complying with Government regulations in the respective markets. The Directors have identified the following business risks which may impact on the future performance of the Group:

Competition

To date, Vita Life has demonstrated that it can compete effectively in the healthcare market in both Australia and Asia. The healthcare industry is highly competitive and characterised by many companies supplying much of the global market requirements. Vita Life's reputation for high quality products and service mitigates this risk.

Currency and Exchange Rate Fluctuations

The financial contribution of the Group will depend on the movement in exchange rates between the Australian dollar and a number of other foreign currencies. The exchange rate between various currencies may fluctuate substantially and the result of these fluctuations may have an adverse impact on the Group's operating results and financial position. The Group does not enter into forward exchange contracts to hedge its anticipated purchase and sale commitments denominated in foreign currencies.

Regulatory

Future expansion of the Company's range of products and services may be governed by regulatory controls in each target market and the Company cannot guarantee that approvals in all target markets will be obtained in the future. The Company's products are required to be registered with the relevant regulatory bodies in each country or relevant jurisdiction. If for any reason such product registrations are delayed, withdrawn or are cancelled, it may have an effect on the sales of products which rely on them in the relevant market or countries.

INDEMNIFICATION AND INSURANCE OF OFFICERS

The Company has agreed to indemnify, to the extent permitted by the Corporations Act 2001, the Directors and Officers of the Company, in respect of certain losses and liabilities which the Director(s) or Officer(s) may incur as a result of, or by reason of being a director or officer of the Company. In accordance with the provisions of the Corporations Act 2001, the Company has a Directors and Officers liability policy which covers all Directors and Officers of the Company. The terms of the policy specifically prohibit disclosure of details of the amount of the insurance cover and the premium paid.

The Company has not, during or since the financial year, indemnified or agreed to indemnify an auditor of the Company or any related body corporate.

ENVIRONMENTAL REGULATIONS

The Group's operations are not subject to any significant environmental regulations under either Commonwealth or State legislation. The Board believes that the Group has adequate systems in place for the management of its environmental requirements as they apply to the Group.



DIRECTORS' MEETINGS

The number of meetings of Directors (including meetings of committees of Directors) held during the year and the number of meetings attended by each Director in the capacity of Director was as follows:

Director	Board Meetings		Audit Committee Meetings		Board Nomination Committee Meetings		Remuneration Committee Meetings	
	Held by members	Attended	Held by members	Attended	Held by members	Attended	Held by members	Attended
Mr Andrew O'Keefe	9	9	*	*	*	*	*	*
Mr Jack Teoh	9	8	*	*	-	-	3	3
Mr Henry G Townsing	9	8	3	3	-	-	3	3
Mr Peter Osborne	9	9	3	3	*	*	*	*

*Not applicable.

AUDITOR'S INDEPENDENCE DECLARATION

The Directors have received an Independence Declaration from the external auditor, Nexia Sydney Audit Pty Limited. A copy of this Declaration follows the Directors' Report.

The Directors are satisfied that the provision of non-audit services is compatible with the general standard of independence for auditors imposed by the *Corporations Act 2001*. The nature and scope of each type of non-audit service provided does not compromise the general principles relating to auditor independence in accordance with APES 110: Code of Ethics for Professional Accountants set by the Accounting Professional and Ethical Standards Board.

Associates of Nexia Sydney Audit Pty Limited received or are due to receive the following amounts for the provision of non-audit services:

	\$'000
Tax compliance services	26
TOTAL	26

ROUNDING OFF

In accordance with Australian Securities and Investments Commission (ASIC) ASIC Corporations (Rounding in Financial/Directors' Reports) Instrument 2016/191, dated 1 April 2016, the amounts in the Financial Report and Directors' Report are been rounded off to the nearest thousand dollars, unless otherwise indicated.

INVESTMENT AND BUSINESS RISK MANAGEMENT

The Board, based on the recommendations of the Managing Director, Mr O'Keefe and the other Directors, make decisions on investments for the Company. The Board considers that the general retention by it, or the power to make the final investment or divestment decision by a majority vote provides an effective review of the investment strategy. A majority of the Directors must approve any modification to the investment parameters applying to the Company's assets. Any modification to the investment strategy is notified to the ASX and any proposed major change in investment strategy is first put to shareholders for their approval.

The Board is also responsible for identifying and monitoring areas of significant business risk. Internal control measures currently adopted by the Board include:

- Monthly reporting to the Board in respect of operations and the Company's financial position, with a comparison of actual results against budget;
- Regular reports to the Board by appropriate members of the management team and/or independent advisers, outlining the nature of particular risks; and
- Other measures which are either in place or can be adopted to manage or mitigate those risks.

SHAREHOLDINGS BY DIRECTORS AND EXECUTIVES

On 23 December 2010, the Board resolved to adopt a new Policy concerning trading in Company securities. An Executive, Director or relevant employees ('employee') must not trade in any securities of the Company at any time when they are in possession of unpublished, price sensitive information in relation to those securities. An employee should not deal in securities of Vita Life Sciences Limited without receiving clearance:

- From a Director in the case an employee;
- From an Executive Director in the case of the Chairman; or
- From the Chairman, in the case of Directors.

Generally, an employee must not be given clearance to deal in any securities of the Company during a prohibited period. A "prohibited period" means:

- The period from year end and preliminary announcement of the full year results (usually 1 January to end February);
- The period from half year end and preliminary announcement of the half year results (usually 1 July to end August); and
- Any other periods advised to employees by the Board (via the Company Secretary).

As required by the ASX Listing Rules, the Company notifies the ASX of any transaction conducted by Directors in the securities of the Company.

ETHICAL STANDARDS

The Board endeavours to ensure that the Directors, officers and employees of Vita Life act with integrity and observe the highest standards of behaviour and business ethics in relation to their corporate activities. All officers and employees are expected to:

- Comply with the law;
- Act in the best interests of the Company;
- Be responsible and accountable for their actions; and
- Observe the ethical principles of fairness, honesty and truthfulness, including disclosure of potential conflicts.

PROCEEDINGS ON BEHALF OF THE COMPANY

No person has applied to the Court under section 237 of the *Corporations Act 2001* for leave to bring proceedings on behalf of the Company, or to intervene in any proceedings to which the Company is a party, for the purpose of taking responsibility on behalf of the Company for all or part of those proceedings.

No proceedings have been brought or intervened in on behalf of the Company with leave of the Court under section 237 of the *Corporations Act 2001*.

REMUNERATION REPORT (Audited)

The Remuneration Report outlines Directors' and Executives' remuneration arrangements of the Company and the Group and the remuneration disclosures required in accordance with the requirements of the *Corporations Act 2001* and its Regulations.

For the purposes of this report Key Management Personnel of the Group are defined as those persons having authority and responsibility for planning, directing and controlling the major activities of the Company and the Group, directly or indirectly, including any Director (whether executive or otherwise) of the Company.

For the purposes of this report, the term "executive" encompasses the Chief Executive/Managing Director, Senior Executives, General Managers and Secretaries of the parent and the Group.

Remuneration committee

The Remuneration Committee comprised Mr Townsing, Chairman of the Remuneration Committee, and Mr Teoh during the financial year. The Remuneration Committee is responsible for:

- Reviewing and approving the remuneration of Directors and other senior executives; and
- Reviewing the remuneration policies of the Company generally.

Total remuneration paid (excluding Share Based Payments expense) for all existing non-executive Directors during the financial year was \$173,500 (2023: \$136,821). These fees paid are within the aggregate remuneration of \$200,000 (2023: \$200,000) for all non-executive Directors as approved by shareholders at the Annual General Meeting (AGM) held on 28 May 2021.

Remuneration philosophy

The performance of the Company depends upon the quality of its Directors and Executives. To prosper, the Company must attract, motivate and retain highly skilled Directors and Executives.

To this end, the Company embodies the following principles in its remuneration framework:

- Provide competitive rewards to attract high calibre executives;
- Link executive rewards to the performance of the Company and the creation of shareholders' value;
- Have a significant portion of executive remuneration "at risk"; and
- Establish appropriate, demanding performance hurdles for variable executive remuneration.

Remuneration structure

In accordance with best practice corporate governance, the structure of Non-Executive Directors and Executives' remuneration is separate and distinct.

Non-executive director remuneration

Objective

The Board seeks to set aggregate remuneration at a level that provides the Company with the ability to attract and retain Directors of the highest calibre, whilst incurring a cost that is acceptable to shareholders.

Structure

The Constitution and the ASX Listing Rules specify that the aggregate remuneration of non-executive Directors shall be determined from time to time by a general meeting. The latest determination was at the Annual General Meeting held on 28 May 2021 when shareholders approved an aggregate remuneration of \$200,000 per year.

The amount of aggregate remuneration sought to be approved by shareholders and the fee structure is reviewed annually. The Board considers advice from external consultants as well as the fees paid to non-executive Directors of comparable companies when undertaking the annual review process.

Each Director receives a fee (as set out in the Remuneration of Key Management Personnel table) for being a Director of the Company. Directors' fees cover all main Board activities and the membership of committees. There are no additional fees for committee membership. These fees exclude any additional "fee for service" based on arrangements with the Company, which may be agreed from time to time. Agreed out of pocket expenses are payable in addition to Directors' fees. There are no retirement or other long service benefits that accrue upon appointment to the Board. Retiring non-executive Directors are not currently entitled to receive a retirement allowance.

REMUNERATION REPORT (CONTINUED)

Executive remuneration

Objective

The Company aims to reward executives with a level and mix of remuneration commensurate with their position and responsibilities within the Company so as to:

- Reward executives for Company, business unit and individual performance against targets set by reference to appropriate benchmarks;
- Align the interests of executives with those of shareholders; and
- Ensure total remuneration is competitive by market standards.

In determining the level and make-up of executive remuneration, the Remuneration Committee engages external consultants as needed to provide independent advice and the recommendations of the Managing Director.

Structure

The Remuneration Committee has entered into a detailed contract of employment with the Managing Director and a standard contract with other executives. Details of these contracts are provided below.

Remuneration consists of the following key elements:

- Fixed remuneration (base salary, superannuation and non-monetary benefits); and
- Variable remuneration
 - Short term incentive; and
 - Long term incentive.

The proportion of fixed remuneration and variable remuneration (potential short term and long term incentives) for each executive is set out in the Remuneration of Key Management Personnel table.

Fixed Remuneration

Objective

Fixed remuneration is reviewed annually by the Remuneration Committee. The process consists of a review of Company, business unit and individual performance, relevant comparative remuneration in the market and internally and, where appropriate, external

advice on policies and practices. As noted above, the Committee has access to external advice independent of management.

Structure

Executives are given the opportunity to receive their fixed (primary) remuneration in a variety of forms including cash and fringe benefits. It is intended that the manner of payment chosen will be optimal for the recipient without creating undue cost for the Group. The fixed remuneration component of executives is detailed in the Remuneration of Key Management Personnel table.

Variable remuneration - Short Term Incentive ("STI")

Objective

The objective of the STI is to link the achievement of the Group's operational targets with remuneration received by the executives charged with meeting those targets. The total potential STI available is set at a level so as to provide sufficient incentive to the executive to achieve the operational targets and such that the cost to the Group is reasonable in the circumstances.

Structure

Actual STI payments granted to each executive depend on the extent to which specific targets set at the beginning of the year are met. The targets consist of a number of Key Performance Indicators (KPI's) covering both financial and non-financial, corporate and individual measures of performance. Typically included measures are sales, net profit after tax, customer service, risk management and leadership/team contribution. These measures were chosen as they represent the key drivers for short term success of the business and provide a framework for long term value.

The Group has predetermined benchmarks that must be met in order to trigger payments under the STI scheme. On an annual basis, after consideration of performance against KPI's, the Remuneration Committee, in line with their responsibilities, determine the amount, if any, of the short term incentive to be paid to each executive. This process usually occurs within 3 months of reporting date.

The aggregate of annual STI payments available for executives across the Group is subject to the approval of the Remuneration Committee. Payments are delivered as a cash bonus in the following reporting period. Participation in the Short Term Incentive Plan is at the Directors' discretion.

Variable remuneration – Long Term Incentives

Objective

The Company's established Long Term Incentive Plan ("Plan") encourages employees or officers to share in the ownership of the Company, in order to promote the long-term success of the Company.

The plan was implemented in 2014 and at the date of this report, the Company had allocated 4,060,000 unexpired plan shares equivalent to 7.2% of the Company's capital. The principal terms and conditions of the Plan are:

- The Company lends money on a non-recourse basis to employees to buy Company shares at an interest rate as determined by the Remuneration Committee. Interest to be paid is to be derived from dividends paid by the Company or capitalised against the loan;
- The total allocation of share capital able to be issued is not to exceed 10.0% of issued capital;
- The term of the loan is up to 5 years at which point all outstanding monies must be repaid or the shares are forfeited;
- Hurdles are as determined by the Remuneration Committee and approved by the Board. Where hurdles are not met the Plan shares will be forfeited and the employee will not be required to make further payment;
- Vesting periods are as determined by the Remuneration Committee and approved by the Board; and
- Any dividends paid will be applied to the principal and or interest charged on the loan.

REMUNERATION REPORT (CONTINUED)

Employment contracts

Managing Director

Mr Andrew O'Keefe was appointed as the Managing Director on 1 January 2017.

The principal terms of Mr O'Keefe's contract are:

- Remuneration of \$772,868 (including superannuation) for the year ended 31 December 2024. The remuneration is reviewed by the Remuneration Committee on a yearly basis.
- Mr O'Keefe is entitled to receive Plan shares subject to shareholders' approval. Refer to Note 23, Share Based Payment Plans of the financial statements for information on Plan shares issued to Mr O'Keefe.
- Mr O'Keefe may be entitled to receive a bonus on achieving certain benchmarks and targets.

- The Company may terminate Mr O'Keefe's employment agreement by providing 6 months' written notice.
- The Company may terminate the contract at any time without notice if serious misconduct has occurred.
- Mr O'Keefe may resign by providing 6 months' written notice.

Other Executives (standard contracts)

All executives have rolling contracts. The Company may terminate the executive's employment agreement by providing (depending on the individual's contract) between 1 and 3 months' written notice or providing payment in lieu of the notice period (based on the fixed component of the executive's remuneration). Where termination with cause occurs the executive is only entitled to that portion of remuneration that is fixed, and only up to the date of termination.

Related Parties

The Directors disclose any conflict of interest in Directors' meetings as per the requirements under the Corporations Act (2001). Any disclosures that are considered to fall under the definition of related parties as per AASB 124 "Related Party Disclosures" are made in the Directors' meetings and minuted.



REMUNERATION REPORT (CONTINUED)

Remuneration of Key Management Personnel

2024	Salary & Fees	Short term incentive	Long term Incentive Plan (share based payment)	Other long term benefits	Post employment benefits Superannuation	Total	Performance Related
	\$	\$	\$	\$	\$	\$	%
Directors							
Mr Henry Townsing Chairman	80,000	-	31,244	-	9,000	120,244	n/a
Andrew O'Keefe Managing Director	442,000	144,242	150,592	7,368	28,666	772,868	18.7
Mr Jack Teoh Non-executive Director	40,000	-	-	-	4,500	44,500	n/a
Mr Peter Osborne Non-executive Director	40,000	-	-	-	-	40,000	n/a
Total Directors Compensation	602,000	144,242	181,836	7,368	42,166	977,612	14.8
Key Management Personnel							
Chin L Khoo CFO & Company Secretary	216,001	17,360	62,047	4,290	24,092	323,790	5.4
K S Beh Country Manager - Malaysia & Singapore	350,794	81,062	66,326	-	28,620	526,802	15.4
Shaun Rutherford CEO Australia	300,000	131,400	66,326	5,662	28,666	532,054	24.7
Melissa Pereira Group Marketing Manager	141,970	6,000	29,300	3,351	16,632	197,253	3.0
Total Key Management Compensation	1,008,765	235,822	223,999	13,303	98,010	1,579,899	14.9
Grand total	1,610,765	380,064	405,835	20,671	140,176	2,557,511	14.9

REMUNERATION REPORT (CONTINUED)
Remuneration of Key Management Personnel

2023	Salary & Fees	Short Term Incentive	Long term Incentive Plan (share based payment)	Other long term benefits	Post employment benefits Superannuation	Total	Performance Related
	\$	\$	\$	\$	\$	\$	%
Directors							
Mr Henry Townsing Chairman	67,167	-	62,489	-	7,243	136,899	n/a
Andrew O'Keefe Managing Director	442,000	86,500	264,442	7,368	26,346	826,656	10.5
Mr Gregory Ralph Non-executive Director (deceased 6 Apr 2023)	7,728	-	-	-	811	8,539	n/a
Mr Jack Teoh Non-executive Director	33,583	-	-	-	3,622	37,205	n/a
Mr Peter Osborne Non-executive Director (appointed on 1 Aug 2023)	16,667	-	-	-	-	16,667	n/a
Total Directors Compensation	567,145	86,500	326,931	7,368	38,022	1,025,966	8.4
Key Management Personnel							
Chin L Khoo CFO & Company Secretary	208,316	14,000	97,033	4,232	23,249	346,830	4.0
K S Beh Country Manager - Malaysia & Singapore	336,969	90,643	97,033	-	20,902	545,547	16.6
Shaun Rutherford [*] CEO Australia	286,855	92,500	97,033	6,717	26,346	509,451	18.2
Melissa Pereira [*] Group Marketing Manager	29,874	8,000	32,923	1,637	4,057	76,491	10.4
Total Key Management Compensation	862,014	205,143	324,022	12,586	74,554	1,478,319	13.9
Grand total	1,429,159	291,643	650,953	19,954	112,576	2,504,285	11.6

^{*} Mr Shaun Rutherford was appointed as the Chief Executive Officer of Herbs of Gold Pty Ltd in Australia from 1 Feb 2023

^{*} Ms Pereira was on maternity leave from 8 Sept 2022 to 19 Sept 2023

EQUITY HOLDINGS AND TRANSACTIONS

The number of ordinary shares in the Company held by each specified Director or specified executive, including their personally-related entities, during the 2024 and 2023 financial years are as follows:

2024		At 1 January 2024	Purchases	LTIP Shares: Allocated	Disposal	At 31 December 2024
DIRECTORS						
Mr Andrew O'Keefe	Beneficial Interest	1,510,000	-	300,000	(920,000)	890,000
Mr Peter Osborne	Non beneficial interest	15,274	10,000	-	-	25,274
Mr Henry G Townsing	Beneficial Interest	315,270	-	-	(300,000)	15,270
	Non beneficial interest	594,744	-	-	(100,000)	494,744
KEY MANAGEMENT PERSONNEL						
Mr Shaun Rutherford	Beneficial Interest	525,000	-	150,000	(352,050)	322,950
	Non beneficial interest	25,357	-	-	-	25,357
Mr Chin L Khoo	Beneficial Interest	566,000	-	125,000	(337,652)	353,348
	Non beneficial interest	10,000	-	-	-	10,000
Mrs Melissa Pereira	Beneficial Interest	175,000	-	75,000	(175,000)	75,000
Ms K S Beh	Beneficial Interest	605,000	-	150,000	(230,110)	524,890
Total		4,341,645	10,000	800,000	(2,414,812)	2,736,833
2023		At 1 January 2023	Purchases	LTIP Shares: Allocated	Disposal	At 31 December 2023
DIRECTORS						
Mr Andrew O'Keefe	Beneficial Interest	1,510,000	-	-	-	1,510,000
Mr Peter Osborne	Non beneficial interest	-	15,274	-	-	15,274
Mr Henry G Townsing	Beneficial Interest	315,270	-	-	-	315,270
	Non beneficial interest	697,338	-	-	(102,594)	594,744
KEY MANAGEMENT PERSONNEL						
Mr Shaun Rutherford	Beneficial Interest	525,000	-	-	-	525,000
	Non beneficial interest	25,357	-	-	-	25,357
Mr Chin L Khoo	Beneficial Interest	606,000	-	-	(40,000)	566,000
	Non beneficial interest	10,000	-	-	-	10,000
Mrs Melissa Pereira	Beneficial Interest	175,000	-	-	-	175,000
Ms K S Beh	Beneficial Interest	605,000	-	-	-	605,000
Total		4,468,965	15,274	-	(142,594)	4,341,645

^a Declared as non relevant interest under S 609(9) of the Corporations Act

(1) Any Directors or Key Management Personnel as disclosed in the remuneration tables at pages 17 and 18 who are not explicitly referenced in the tables above did not hold any ordinary shares in the Company for the periods shown.

LONG TERM INCENTIVE PLAN SHARES

The following table discloses the details of Long Term Incentive Plan Shares on issue to Directors and Key Management Personnel as at 31 December 2024.

	Number of LTIP shares on issue	Fair value at grant date	Exercise price per LTIP share	Amount payable	Terms - years	Expiry Date	Performance Hurdle
DIRECTORS							
Andrew O'Keefe	300,000	0.582	2.30	690,000	2.1	30/06/2026	Cumulative EBITDA of VLS for 2 years ending 31 Dec 2024 and 31 Dec 2025 being not less than \$26,300,000
Shaun Rutherford	150,000	0.582	2.30	345,000	2.1	30/6/2026	Cumulative EBITDA of VLS for 2 years ending 31 Dec 2024 and 31 Dec 2025 being not less than \$26,300,000
Melissa Pereira	75,000	0.582	2.30	172,500	2.1	30/6/2026	Cumulative EBITDA of VLS for 2 years ending 31 Dec 2024 and 31 Dec 2025 being not less than \$26,300,000
Chin L Khoo	125,000	0.582	2.30	287,500	2.1	30/6/2026	Cumulative EBITDA of VLS for 2 years ending 31 Dec 2024 and 31 Dec 2025 being not less than \$26,300,000
K S Beh	150,000	0.582	2.30	345,000	2.1	30/6/2026	Cumulative EBITDA of VLS for 2 years ending 31 Dec 2024 and 31 Dec 2025 being not less than \$26,300,000
Total	800,000			1,840,000			

END OF REMUNERATION REPORT

Signed in accordance with a resolution of the Directors.



Andrew O'Keefe
 Managing Director
 24 March 2025

For personal use only

Auditor's Independence Declaration

The Board of Directors
Vita Life Sciences Limited
Unit 1/102 Bath Road
Kirrawee NSW 2232

To the Board of Directors of Vita Life Sciences Limited,

Auditor's Independence Declaration under section 307C of the *Corporations Act 2001*

As lead auditor for the audit of the consolidated financial statements of Vita Life Sciences Limited for the financial year ended 31 December 2024, I declare that to the best of my knowledge and belief, there have been no contraventions of:

- (a) the auditor independence requirements of the *Corporations Act 2001* in relation to the audit; and
- (b) any applicable code of professional conduct in relation to the audit.

Yours sincerely,



Nexia Sydney Audit Pty Limited



Stephen Fisher
Director

Dated: 24 March 2025
Sydney

For personal use only

2024 Financial Report



CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

FOR THE YEAR ENDED 31 DECEMBER	Notes	Consolidated	
		2024 \$'000	2023 \$'000
CONTINUING OPERATIONS			
Sale of goods		79,505	73,427
Cost of sales		(32,264)	(31,045)
Gross profit		47,241	42,382
Other gain (loss)	4 (a)	155	(183)
Distribution expenses		(6,586)	(5,267)
Marketing expenses		(7,305)	(5,365)
Occupancy expenses		(1,006)	(832)
Administrative expenses	4 (b)	(20,290)	(18,703)
Fair value adjustment on building		-	335
Other expenses	4 (c)	(398)	(339)
Profit from continuing operations before interest and taxes		11,811	12,028
Finance income	4 (d)	1,039	558
Finance costs	4 (e)	(209)	(135)
Profit before income tax		12,641	12,451
Income tax expense	6	(3,862)	(3,373)
Net profit for the year		8,779	9,078
Other comprehensive income after income tax			
Items that will be reclassified subsequently to profit or loss when specific conditions are met:			
Exchange differences on translating foreign controlled entities		2,444	(764)
Items that will not be reclassified subsequently to profit or loss when specific conditions are met:			
Fair value adjustment on land		-	534
Other comprehensive income (loss) for the year, net of income tax		2,444	(230)
Total comprehensive income for the year		11,223	8,848
Net profit/(loss) for the year attributable to:			
Non-controlling interest		(5)	(2)
Members of the parent		8,784	9,080
		8,779	9,078
Total comprehensive income attributable to:			
Non-controlling interest		(5)	5
Members of the parent		11,228	8,843
		11,223	8,848
Earnings per share (cents per share)			
- basic earnings per share	5	15.79	16.92
- diluted earnings per share	5	15.79	16.60

THE ACCOMPANYING NOTES SHOULD BE READ IN CONJUNCTION WITH THE ABOVE CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME.

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

AS AT 31 DECEMBER	Notes	Consolidated	
		2024 \$'000	2023 \$'000
ASSETS			
Current Assets			
Cash and cash equivalents	7	28,601	24,630
Trade and other receivables	8	11,999	11,215
Inventories	9	16,599	11,153
Other assets	10	1,699	1,291
Total Current Assets		58,898	48,289
Non Current Assets			
Property, plant and equipment	11	10,329	9,170
Intangible assets		50	26
Deferred tax assets	6 (c)	2,615	2,322
Total Non Current Assets		12,994	11,518
Total Assets		71,892	59,807
LIABILITIES			
Current Liabilities			
Trade and other payables	12	11,745	9,681
Current tax liability		581	74
Employee entitlements	13	1,840	2,155
Contract return liability	14	4,805	4,095
Lease liability	15	303	211
Total Current Liabilities		19,274	16,216
Non Current Liabilities			
Employee entitlements	13	121	84
Lease liability	15	214	176
Total Non Current Liabilities		335	260
Total Liabilities		19,609	16,476
Net Assets		52,283	43,331
EQUITY			
Contributed equity	16	45,030	42,567
Accumulated profit (losses)		846	(2,769)
Employee share based payments reserve		2,753	2,318
Share options reserve		992	992
Revaluation Reserve		859	859
Foreign currency translation reserve		1,874	(570)
Parent entity interest		52,354	43,397
Non-controlling interest		(71)	(66)
Total Equity		52,283	43,331

THE ACCOMPANYING NOTES SHOULD BE READ IN CONJUNCTION WITH THE ABOVE CONSOLIDATED STATEMENT OF FINANCIAL POSITION.

CONSOLIDATED STATEMENT OF CASH FLOWS

FOR THE YEAR ENDED 31 DECEMBER	Notes	Consolidated	
		2024 \$'000	2023 \$'000
CASH FLOWS FROM OPERATING ACTIVITIES			
Receipts from customers		83,059	76,446
Payments to suppliers and employees		(74,379)	(60,551)
Income tax paid		(3,355)	(3,336)
Interest received		1,039	558
Bank charges		(209)	(135)
Net cash flows provided by operating activities	7(d)	6,155	12,982
CASH FLOWS USED IN AN INVESTING ACTIVITY			
Purchase of property, plant and equipment		(198)	(660)
Net cash flows used in an investing activity		(198)	(660)
CASH FLOWS FROM FINANCING ACTIVITIES			
Payment of leases		(286)	(171)
Dividends paid		(5,169)	(3,367)
LTIP repayments		3,856	871
Shares bought back (net of costs)		(1,393)	(208)
Net cash flows used in financing activities		(2,992)	(2,875)
Net increase in cash and cash equivalents		2,965	9,447
Net foreign exchange differences		1,006	(505)
Cash and cash equivalents at beginning of the year		24,630	15,688
Cash and cash equivalents at end of the year	7	28,601	24,630

THE ACCOMPANYING NOTES SHOULD BE READ IN CONJUNCTION WITH THE ABOVE CONSOLIDATED STATEMENT OF CASH FLOWS.

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

	Note	Contributed Equity \$'000	Employee Share Based Payments Reserve \$'000	Share Options Reserve \$'000	Revaluation Reserve \$'000	Accumulated Profit (Losses) \$'000	Foreign Currency Translation Reserve \$'000	Attributable to Equity Holders of Parent \$'000	Non- controlling Interest \$'000	Total \$'000
Balance at 1 January 2024		42,567	2,318	992	859	(2,769)	(570)	43,397	(66)	43,331
Comprehensive income										
Profit attributable to members of parent entity		-	-	-	-	8,784	-	8,784	(5)	8,779
Other comprehensive income (loss) for the year		-	-	-	-	-	2,444	2,444	-	2,444
Total comprehensive income (loss) for the year		-	-	-	-	8,784	2,444	11,228	(5)	11,223
Transactions with owners, in their capacity as owners										
Shares bought back	16(a)	(1,393)	-	-	-	-	-	(1,393)	-	(1,393)
Loan repayment on shares issued	16(b)	3,856	-	-	-	-	-	3,856	-	3,856
Employee share based expense		-	435	-	-	-	-	435	-	435
Dividends paid	16(d)	-	-	-	-	(5,169)	-	(5,169)	-	(5,169)
Total transactions with owners		2,463	435	-	-	(5,169)	-	(2,271)	-	(2,271)
Balance at 31 December 2024		45,030	2,753	992	859	846	1,874	52,354	(71)	52,283

THE ACCOMPANYING NOTES SHOULD BE READ IN CONJUNCTION WITH THE ABOVE CONSOLIDATED STATEMENT OF CHANGES IN EQUITY.

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY (CONTINUED)

	Note	Contributed Equity \$'000	Employee Share Based Payments Reserve \$'000	Share Options Reserve \$'000	Revaluation Reserve \$'000	Accumulated Losses \$'000	Foreign Currency Translation Reserve \$'000	Attributable to Equity Holders of Parent \$'000	Non- controlling Interest \$'000	Total \$'000
Balance at 1 January 2023		41,904	1,634	992	325	(8,482)	201	36,574	(71)	36,503
Comprehensive income										
Profit attributable to members of parent entity		-	-	-	-	9,080	-	9,080	(2)	9,078
Other comprehensive income (loss) for the year		-	-	-	534	-	(771)	(237)	7	(230)
Total comprehensive income (loss) for the year		-	-	-	534	9,080	(771)	8,843	5	8,848
Transactions with owners, in their capacity as owners										
Shares bought back	16(a)	(208)	-	-	-	-	-	(208)	-	(208)
Loan Repayment on Shares issued	16(b)	871	-	-	-	-	-	871	-	871
Employee share based expense		-	684	-	-	-	-	684	-	684
Dividends paid	16(d)	-	-	-	-	(3,367)	-	(3,367)	-	(3,367)
Total transactions with owners		663	684	-	-	(3,367)	-	(2,020)	-	(2,020)
Balance at 31 December 2023		42,567	2,318	992	859	(2,769)	(570)	43,397	(66)	43,331

THE ACCOMPANYING NOTES SHOULD BE READ IN CONJUNCTION WITH THE ABOVE CONSOLIDATED STATEMENT OF CHANGES IN EQUITY.

For personal use only

Notes to the Financial Statements



FOR THE YEAR ENDED 31 DECEMBER 2024

1 CORPORATE INFORMATION

The financial report of Vita Life Sciences Limited for the year ended 31 December 2024 was authorised for issue in accordance with a resolution of the Directors on the date of this report.

Vita Life Sciences Limited is a Company limited by shares incorporated in Australia whose shares are publicly traded on the Australian Securities Exchange ("ASX") under the code VLS. The nature of the operations and principal activities of Vita Life Sciences Limited and its controlled entities are described in the Directors' Report.

2 SUMMARY OF MATERIAL ACCOUNTING POLICIES**(a) Basis of preparation**

The financial statements are general purpose financial statements that have been prepared in accordance with Australian Accounting Standards, Australian Accounting Interpretations, other authoritative pronouncements of the Australian Accounting Standards Board (AASB) and International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB) and the *Corporations Act 2001*. The Group is a for-profit entity for financial reporting purposes under Australian Accounting Standards.

Australian Accounting Standards set out accounting policies that the AASB has concluded would result in financial statements containing relevant and reliable information about transactions, events and conditions. Compliance with Australian Accounting Standards ensures that the financial statements and notes also comply with International Financial Reporting Standards as issued by the IASB. Material accounting policies adopted in the preparation of these financial statements are presented below and have been consistently applied unless stated otherwise.

Except for cash flow information, the financial statements have been prepared on an accruals basis and are based on historical costs, modified, where applicable, by the measurement at fair value of selected non-current assets, financial assets and financial liabilities.

(b) Statement of compliance

The Financial Report complies with Australian Accounting Standards, which include Australian equivalents to International Financial Reporting Standards ("AIFRS"). Compliance with AIFRS ensures that the financial report, comprising the financial statements and notes thereto, complies with International Financial Reporting Standards ("IFRS").

(c) Basis of consolidation

The consolidated financial statements comprise the financial statements of Vita Life Sciences Limited and its subsidiaries ("the Group") as at 31 December 2024. Interests in associates are equity accounted and are not part of the consolidated Group.

Subsidiaries are all those entities over which the consolidated entity has control. The consolidated entity controls an entity when the consolidated entity is exposed to, or has the right to, variable returns from its involvement with the entity and has the ability to affect those returns through its power to direct the activities of the entity. Subsidiaries are fully consolidated from the date on which control is transferred to the consolidated entity. They are de-consolidated from the date that control ceases.

The financial statements of subsidiaries are prepared for the same reporting period as the parent company, using consistent accounting policies.

In preparing the consolidated financial statements, all intercompany balances and transactions, income and expenses and profit and losses resulting from intra-group transactions have been eliminated in full.

Subsidiaries are fully consolidated from the date on which control is obtained by the Group and cease to be consolidated from the date on which control is transferred out of the Group.

Investments in subsidiaries held by Vita Life Sciences Limited are accounted for at cost in the separate financial statements of the parent entity.

The acquisition of subsidiaries is accounted for using the purchase method of accounting. The purchase method of

accounting involves allocating the cost of the business combination to the fair value of the assets acquired and the liabilities and contingent liabilities assumed at the date of acquisition.

Minority interests represent the interests in Vita Life Sciences (Thailand) Co. Ltd and Vitahealth (Thailand) Co. Ltd not held by the Group. Minority interests are allocated their share of net profit or loss after tax in the statement of comprehensive income and are presented within Equity in the consolidated statement of financial position, separately from the parent shareholders' equity.

Operating segments are presented using the 'management approach' where information presented is on the same basis as the internal reports provided to the Chief Operating Decision Makers ('CODM'). The CODM is responsible for the allocation of resources to operating segments and assessing their performance.

(d) Foreign currency translation*(i) Functional and presentation currency*

Both the functional and presentation currency of Vita Life Sciences Limited and its Australian subsidiaries are Australian dollars (\$).

The functional currency of the main operating overseas subsidiaries Vita Healthcare Asia Pacific Sdn Bhd, VitaHealth Malaysia Sdn Bhd, Herbs of Gold Sdn Bhd, Vita Life Sciences Sdn Bhd and Pharma Direct Sdn Bhd are Malaysian Ringgit (RM), whilst Vitahealth IP Pte Ltd, VitaHealth Asia Pacific (S) Pte Ltd, Herbs of Gold (Singapore) Pte Ltd and Vita Corporation Pte Limited are Singapore Dollars (SGD), Herbs of Gold (Shanghai) Company Ltd is Chinese Renminbi (RMB), PT Vita Health Indonesia is Indonesian Rupiah (IDR), Vita Health (Thailand) Co Ltd and Vita Life Sciences (Thailand) Co Ltd are Thai Baht (THB) and Vita Health (Vietnam) Company Limited is Vietnamese Dong (VND).

(ii) Transactions and balances

Transactions in foreign currencies are initially recorded in the functional currency by applying the exchange rates ruling at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies

FOR THE YEAR ENDED 31 DECEMBER 2024 (CONTINUED)

are retranslated at the rate of exchange ruling at the balance date.

Non-monetary items that are measured in terms of historical cost in a foreign currency are translated using the exchange rate as at the date of the initial transaction. Non-monetary items measured at fair value in a foreign currency are translated using the exchange rate at the date when the fair value was determined.

The exchange differences arising on the retranslation of foreign subsidiaries are taken directly to a separate component of equity.

On disposal of a foreign entity, the deferred cumulative amount recognised in equity relating to that particular foreign operation is recognised in the *Consolidated Statement of Profit and Loss and Other Comprehensive Income*.

(e) Cash and cash equivalents

Cash and cash equivalents in the statement of financial position comprise cash at bank and on hand and short-term deposits that are readily convertible to known amounts of cash and which are subject to an insignificant risk of change in value.

For the purposes of the Statement of Cash Flows, cash and cash equivalents consist of cash and cash equivalents as defined above.

(f) Trade and other receivables

Trade receivables, which generally have 30-90 days terms, are recognised initially at fair value and subsequently measured at amortised cost using the effective interest method, less an allowance for impairment using the expected credit losses model.

Collectability of trade receivables is reviewed on an ongoing basis at an operating unit level. Individual debts that are known to be uncollectible are written off when identified. The consolidated entity has applied the simplified approach to measuring expected credit losses, which uses a lifetime expected loss allowance. To measure the expected credit losses, trade receivables have been grouped based on days overdue.

(g) Inventory

Inventories including raw materials are valued at the lower of cost and net realisable value. Net realisable value is the estimated selling price in the ordinary course of business, less estimated costs of completion and the estimated selling costs.

Costs incurred in bringing each product to its present location and condition are accounted for as follows:

- Raw materials – purchase cost on a first-in, first-out basis.
- Finished goods and work-in-progress – cost of direct materials and labour and a proportion of manufacturing overheads based on normal operating capacity but excluding borrowing costs.

(h) Property, plant and equipment

Land and buildings are shown at fair value and are restated at its revalued amount, based on periodic, at least every 5 years, valuations by an independent professional valuer, less subsequent depreciation and impairment for buildings. Valuations are undertaken more frequently if there is a material change in the fair value relative to the carrying amount. Any increases in carrying amount are recognised in the asset revaluation reserve, unless they offset previous decreases in the carrying amount of the same asset, in which case they are taken to the profit or loss in the statement of comprehensive income. Decreases in carrying amounts that offset previous increases of the same asset are recognised against the asset revaluation reserve. All other decreases in carrying amounts are recognised as a loss in the statement of comprehensive income.

All other plant and equipment are measured at cost less accumulated depreciation and impairment losses.

The cost of fixed assets constructed within the economic entity includes the cost of materials, direct labour, borrowing costs and an appropriate proportion of fixed and variable overheads. Subsequent costs are included in the asset's carrying amount or recognised as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the group and the cost of the item can be reliably. All other repairs and maintenance are charged to the statement of comprehensive income during the financial period in which they are incurred.

Depreciation

The depreciable amounts of all fixed assets including capitalised lease assets are depreciated on a straight-line basis over the estimated useful lives. Leasehold improvements are depreciated over the shorter of either the unexpired period of the lease or the estimated useful lives of the improvements.

An item of property, plant and equipment is derecognised upon disposal or when no future economic benefits are expected to arise from the continued use of the asset. Any gain or loss arising on de-recognition of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the item) is included in the *Consolidated Statement of Profit and Loss and Other Comprehensive Income* in the year the item is derecognised.

Depreciation is calculated on a straight-line basis over the estimated useful life of the asset as follows:

	Rate	Method
Buildings	2%	Straight-line method
Plant and equipment	10-33%	Straight-line method
Leasehold Improvements	20-50%	Straight-line method
Motor Vehicles	20-50%	Straight-line method

FOR THE YEAR ENDED 31 DECEMBER 2024 (CONTINUED)

Right-of-use assets

A right-of-use asset is recognised at the commencement date of a lease. The right-of-use asset is measured at cost, which comprises the initial amount of the lease liability, adjusted for, as applicable, any lease payments made at or before the commencement date net of any lease incentives received, any initial direct costs incurred, and, except where included in the cost of inventories, an estimate of costs expected to be incurred for dismantling and removing the underlying asset, and restoring the site or asset.

Right-of-use assets are depreciated on a straight-line basis over the unexpired period of the lease or the estimated useful life of the asset, whichever is the shorter. Where the Group expects to obtain ownership of the leased asset at the end of the lease term, the depreciation is over its estimated useful life. Right-of-use assets are subject to impairment or adjusted for any remeasurement of lease liabilities.

The Group has elected not to recognise a right-of-use asset and corresponding lease liability for short-term leases with terms of 12 months or less and leases of low-value assets. Lease payments on these assets are expensed to profit or loss as incurred.

(i) Intangibles

Intangibles

Intangible assets acquired separately are capitalised at cost and from a business combination are capitalised at fair value as at the date of acquisition. Following initial recognition, intangible assets are carried at cost less any accumulated amortisation and any accumulated impairment losses. Internally generated intangible assets, excluding development costs, created within the business are not capitalised and expenditure is charged against profits in the year in which the expenditure is incurred.

The useful lives of these intangible assets are assessed to be either finite or indefinite. Intangible assets with finite lives are amortised over the useful life and tested for impairment whenever there is an indication that the intangible asset may be

impaired. The amortisation period and the amortisation method for an intangible asset with a finite useful life are reviewed at least at each financial year-end. Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the assets are accounted for prospectively by changing the amortisation period or method, as appropriate, which is a change in accounting estimate. The amortisation expense on intangible assets with finite lives is recognised in profit or loss in the expense category consistent with the function of the intangible asset.

Intangible assets with indefinite useful lives are tested for impairment annually either individually or at that cash-generating unit level. Such intangibles are not amortised. The useful life of an intangible asset with an indefinite life is reviewed each reporting period to determine whether indefinite life assessment continues to be supportable. If not, the change in the useful life assessment from indefinite to finite is accounted for as a change in an accounting estimate and is thus accounted for on prospective basis.

Impairment of non-financial assets

Intangible assets that have an indefinite useful life are not subject to amortisation and are tested annually for impairment or more frequently if events or changes in circumstances indicate that they might be impaired. Other assets are tested for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.

An impairment loss is recognised for the amount by which the asset's carrying amount exceeds its recoverable amount.

Recoverable amount is the higher of an asset's fair value less costs to sell and value in use. For the purposes of assessing impairment, assets are grouped at the lowest level for which there are separately identifiable cash inflows which are largely independent of the cash inflows from other assets or group of assets (cash-generating units). Non-financial assets other than goodwill that suffer impairment are tested for possible reversal of the impairment whenever events or changes in circumstances indicate that the impairment may have reversed.

(j) Trade and other payables and Contract Return Liability

Trade payables and other payables are carried at amortised cost and represent liabilities for goods and services provided to the Group prior to the end of the financial year that are unpaid and arise when the Group becomes obliged to make future payments in respect of the purchase of these goods and services. Trade payables are normally settled within 30 to 90 days.

Contract Return Liability

Contract return liability is recognised where the Group receives consideration from a customer and expects to refund some, or all, of that consideration to the customer. A contract return liability is measured at the amount of consideration received or receivable for which the consolidated entity does not expect to be entitled and is updated at the end of each reporting period for changes in circumstances. Historical data is used across product range to estimate such returns at the time of sale based on an expected value methodology.

A summary of the policies applied to the Group's intangible asset is as follows:

	Development costs
Useful lives	Finite
Method used Internally generated or Acquired	3 years – Straight line Internally generated
Impairment test or Recoverable amount testing	Amortisation method reviewed at each financial year-end annually for indicator of impairment

FOR THE YEAR ENDED 31 DECEMBER 2024 (CONTINUED)

(k) Interest bearing loans and borrowings

All loans and borrowings are initially recognised at cost, being the fair value of the consideration received net of issue costs associated with the borrowing.

After initial recognition, interest-bearing loans and borrowings are subsequently measured at amortised cost using the effective interest method. Amortised cost is calculated by taking into account any issue costs and any discount or premium on settlement.

Borrowings are classified as current liabilities unless the Group has an unconditional right to defer settlement of the liability for at least 12 months after the balance date.

Borrowing costs

Borrowing costs are recognised as an expense when incurred. Borrowing costs that are directly attributable to the acquisition, construction or production of assets that necessarily take a substantial period of time to prepare for their intended use or sale, are added to the cost of those assets, until such time as the assets are substantially ready for their intended use or sale.

(l) Provisions

Provisions are recognised when the Group has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation.

Where the Group expects some or all of a provision to be reimbursed, for example under an insurance contract, the reimbursement is recognised as a separate asset but only when the reimbursement is virtually certain. The expense relating to any provision is presented in the *Consolidated Statement of Profit and Loss and Other Comprehensive Income* net of any reimbursement.

If the effect of the time value of money is material, provisions are determined by discounting the expected future cash flows

at a pre-tax rate that reflects current market assessments of the time value of money and, where appropriate, the risks specific to the liability. Where discounting is used, the increase in the provision due to the passage of time is recognised as a finance cost.

(m) Employee entitlements

Provision is made for employee benefits accumulated as a result of employees rendering services up to the reporting date. These benefits include wages and salaries, annual leave and long service leave.

Employee benefits expected to be settled within twelve months of the reporting date are measured at their nominal amounts based on remuneration rates which are expected to be paid when the liability is settled plus related on-costs. All other employee benefit liabilities are measured at the present value of the estimated future cash outflows to be made in respect of services provided by employees up to the reporting date. In determining the present value of future cash outflows, the market yield as at the reporting date on 'Group of 100' corporate bonds, which have terms to maturity approximating the terms of the related liability, are used.

Employee benefit expenses and revenues arising in respect of wages and salaries, non-monetary benefits, annual leave, long service leave and other leave benefits and other types of employee benefits, are recognised against profits on a net basis in their respective categories.

(n) Leases

Lease Liabilities

A lease liability is recognised at the commencement date of a lease. The lease liability is initially recognised at the present value of the lease payments to be made over the term of the lease, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the entity's or the Group's incremental borrowing rate. Lease payments comprise of fixed payments less any lease incentives receivable, variable lease payments that

depend on an index or a rate, amounts expected to be paid under residual value guarantees, exercise price of a purchase option when the exercise of the option is reasonably certain to occur, and any anticipated termination penalties. The variable lease payments that do not depend on an index or a rate are expensed in the period in which they are incurred.

Lease liabilities are measured at amortised cost using the effective interest method. The carrying amounts are remeasured if there is a change in the following: future lease payments arising from a change in an index or a rate used; residual guarantee; lease term; certainty of a purchase option and termination penalties. When a lease liability is remeasured, an adjustment is made to the corresponding right-of-use asset, or to profit or loss if the carrying amount of the right-of-use asset is fully written down.

(o) Issued capital

Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of new shares or options are shown in equity as a deduction, net of tax, from the gross proceeds.

(p) Revenue recognition

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Group and the revenue can be reliably measured. The following specific recognition criteria must also be met before revenue is recognised:

Sale of goods

The Group's contracts with customers for the sale of goods generally include one performance obligation. The Group has concluded that revenue from sale of goods should be recognised at the point in time when control of the asset is transferred to the customer, generally on delivery of the goods. However, the amount of revenue to be recognised was affected by variable consideration i.e. transaction price.

Contractual terms and geographical business practice provide retail customers with a right of return of goods up to the

FOR THE YEAR ENDED 31 DECEMBER 2024 (CONTINUED)

point at which they about to expire or have expired. The right of return gives rise to variable consideration which is required to be reflected in the revenue recognised in the period. Revenue should be constrained until such time that any uncertainty in the amount to be recognised is resolved. Revenue recognised by the Group is required to reflect the right of return in its expectation for consideration to be received for a sale.

Interest

Revenue is recognised as the interest accrues (using the effective interest rate method, which is the rate that exactly discounts estimated future cash receipts through the expected life of the financial instrument) to the net carrying amount of the financial asset.

Dividends

Revenue is recognised when the Group's right to receive the payment is established.

(q) Taxes

Current tax assets and liabilities for the current and prior periods are measured at the amount expected to be recovered from or paid to the taxation authorities based on the current period's taxable income. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted at balance date.

Deferred income tax is provided on all temporary differences at the balance date between the tax base of assets and liabilities and their carrying amounts for financial reporting purposes.

Deferred income tax liabilities are recognised for all taxable temporary differences:

- Except where the deferred income tax liability arises from the initial recognition of an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss; and
- In respect of taxable temporary differences associated with investments in subsidiaries, associates and interests in joint ventures, except where the timing of the reversal

of the temporary differences can be controlled and it is probable that the temporary differences will not reverse in the foreseeable future.

Deferred income tax assets are recognised for all deductible temporary differences, carry-forward of unused tax assets and unused tax losses, to the extent that it is probable that taxable profit will be available against which the deductible temporary differences, and the carry-forward of unused tax assets and unused tax losses can be utilised:

- Except where the deferred income tax asset relating to the deductible temporary difference arises from the initial recognition of an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss; and
- In respect of deductible temporary differences associated with investments in subsidiaries, associates and interests in joint ventures, deferred tax assets are only recognised to the extent that it is probable that the temporary differences will reverse in the foreseeable future and taxable profit will be available against which the temporary differences can be utilised.

The carrying amount of deferred income tax assets is reviewed at each balance date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred income tax asset to be utilised.

Unrecognised deferred income tax assets are reassessed at each balance date and are recognised to the extent that it has become probable that future taxable profit will allow the deferred tax asset to be recovered.

Deferred income tax assets and liabilities are measured at the tax rates that are expected to apply to the year when the asset is realised or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted at the balance date.

Tax consolidation

The Company is the head entity of the

tax consolidated group comprising all the Australian wholly owned subsidiaries. The implementation date for the tax consolidated group was for the tax period ended 30 June 2003.

Current tax expense/income, deferred tax liabilities and deferred tax assets arising from temporary differences of the members of the tax consolidated group are recognised in the separate financial statements of the members of the tax consolidated group using a "Stand-Alone Taxpayer" approach by reference to the carrying amounts of assets and liabilities in the separate financial statements of each entity and the tax values applying under consolidation.

Any current tax Australian liabilities (or assets) and deferred tax assets arising from unused tax losses of the subsidiaries is assumed by the head entity in the tax consolidated group and are recognised as amounts receivable from (payable to) other entities in the tax consolidated group. Any difference between these amounts is recognised by the head entity as an equity contribution or distribution.

The Company recognises deferred tax assets arising from unused tax losses of the tax consolidated group to the extent that it is probable that future taxable profits of the tax consolidated group will be available against which the asset can be utilised.

Any subsequent period adjustments to deferred tax assets arising from unused tax losses as a result of revised assessments of the probability of recoverability is recognised by the head entity only.

(r) Other taxes

Revenues, expenses and assets are recognised net of the amount of Goods and Services Tax ("GST") (or its equivalent in non-Australian tax jurisdictions) except:

- Where the GST incurred is not recoverable from the Australian Taxation Office ("ATO") or similar tax authorities outside Australia and, is therefore recognised as part of the asset's cost or as part of the expense item.
- Receivables and payables are stated inclusive of GST.

The net amount of GST recoverable from,

FOR THE YEAR ENDED 31 DECEMBER 2024 (CONTINUED)

or payable to, the ATO is included as part of receivables or payables in the Statement of Financial Position. Cash flows are presented in the Statement of Cash Flows on a gross basis and the GST component of cash flows arising from investing and financing activities, which is recoverable from, or payable to the taxation authority are classified as operating cash flows.

(s) Financial instruments

Financial instruments are initially measured at cost on trade date, which includes transaction costs, when the related contractual rights or obligations exist. Subsequent to initial recognition these instruments are measured as set out below.

Loans and receivables

Loans and receivables are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market and are stated at amortised cost using the effective interest rate method.

De-recognition of financial instruments

Financial assets

A financial asset (or, where applicable, a part of a financial asset or part of a group of similar financial assets) is derecognised when:

- The rights to receive cash flows from the asset have expired;
- The Group retains the right to receive cash flows from the asset, but has assumed an obligation to pay them in full without material delay to a third party under a 'pass-through' arrangement; or
- The Group has transferred its rights to receive cash flows from the asset and either (a) has transferred substantially all the risks and rewards of the asset, or

(b) has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset.

When the Group has transferred its rights to receive cash flows from an asset and has neither transferred nor retained substantially all the risks and rewards of the asset nor transferred control of the asset, the asset is recognised to the extent of the Group's continuing involvement in the asset. Continuing involvement that takes the form of a guarantee over the transferred asset is measured at the lower of the original carrying amount of the asset and the maximum amount of consideration received that the Group could be required to repay.

Financial liabilities

A financial liability is derecognised when the obligation under the liability is discharged or cancelled or expires. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as a de-recognition of the original liability and the recognition of a new liability, and the difference in the respective carrying amounts is recognised in profit or loss.

If, in a subsequent period, the amount of the impairment loss decreases and the decrease can be related objectively to an event occurring after the impairment was recognised, the previously recognised impairment loss is reversed. Any subsequent reversal of an impairment loss is recognised in profit or loss, to the extent that the carrying value of the asset does not exceed its amortised cost at the reversal date.

Financial assets carried at amortised cost

If there is objective evidence that an impairment loss on loans and receivables carried at amortised cost has been incurred, the amount of the loss is measured as the difference between the asset's carrying amount and the present value of estimated future cash flows (excluding future credit losses that have not been incurred)

discounted at the financial asset's original effective interest rate (i.e. the effective interest rate computed at initial recognition). The carrying amount of the asset is reduced either directly or through use of an allowance account. The amount of the loss is recognised in profit or loss.

The Group first assesses whether objective evidence of impairment exists individually for financial assets that are individually significant, and individually or collectively for financial assets that are not individually significant. If it is determined that no objective evidence of impairment exists for an individually assessed financial asset, whether significant or not, the asset is included in a group of financial assets with similar credit risk characteristics and that group of financial assets is collectively assessed for impairment. Assets that are individually assessed for impairment and for which an impairment loss is or continues to be recognised are not included in a collective assessment of impairment.

Financial assets carried at cost

If there is objective evidence that an impairment loss has been incurred on an unquoted equity instrument that is not carried at fair value (because its fair value cannot be reliably measured), or on a derivative asset that is linked to and must be settled by delivery of such an unquoted equity instrument, the amount of the loss is measured as the difference between the asset's carrying amount and the present value of estimated future cash flows, discounted at the current market rate of return for a similar financial asset.

(t) Earnings per share

Basic earnings per share

Basic earnings per share is determined by dividing the net profit/(loss) after income tax attributable to members of the Company by the weighted average number of ordinary shares outstanding during the financial year, adjusted for bonus elements in ordinary shares issued during the year.

Diluted earnings per share

Diluted earnings per share adjust the

FOR THE YEAR ENDED 31 DECEMBER 2024 (CONTINUED)

figures used in the determination of basic earnings per share to take into account the after income tax effect of interest and other financing costs associated with dilutive potential ordinary shares and the weighted average number of shares assumed to have been issued for no consideration in relation to dilutive potential ordinary shares.

(u) Share-based payment transactions

Equity settled transactions

The Group provides benefits to its employees (including key management personnel) in the form of share-based payments, whereby employees render services in exchange for shares or rights over shares (equity-settled transactions).

The cost of these equity-settled transactions with employees is measured by reference to the fair value of the equity instruments at the date at which they are granted. The fair value is determined using the Black-Scholes model. In valuing equity-settled transactions, no account is taken of any vesting conditions, other than conditions linked to the price of the shares of Vita Life Sciences Limited (market conditions) if applicable.

The cost of equity-settled transactions is recognised, together with a corresponding increase in equity, over the period in which the performance and/or service conditions are fulfilled (the vesting period), ending on the date on which the relevant employees become fully entitled to the award (the vesting date).

At each subsequent reporting date until vesting, the cumulative charge to the *Consolidated Statement of Profit and Loss and Other Comprehensive Income* is the product of:

- The grant date fair value of the award;
- The current best estimate of the number of awards that will vest, taking into account such factors as the likelihood of employee turnover during the vesting period and the likelihood of non-market performance conditions being met; and
- The expired portion of the vesting period.

The charge to the *Consolidated Statement of Profit and Loss and Other Comprehensive Income* for the period is the cumulative

amount as calculated above less the amounts already charged in previous periods. There is a corresponding entry to equity.

Until an award has vested, any amounts recorded are contingent and will be adjusted if more or fewer awards are vested than were originally anticipated to do so. Any award subject to a market condition is considered to vest irrespective of whether or not that market condition is fulfilled, provided that all other conditions are satisfied.

If the terms of an equity-settled award are modified, as a minimum an expense is recognised as if the terms had not been modified. An additional expense is recognised for any modification that increases the total fair value of the share-based payment arrangement, or is otherwise beneficial to the employee, as measured at the date of modification.

If an equity-settled award is cancelled, it is treated as if it had vested on the date of cancellation, and any expense not yet recognised for the award is recognised immediately. However, if a new award is substituted for the cancelled award and designated as a replacement award on the date that it is granted, the cancelled and new award are treated as if they were a modification of the original award, as described in the previous paragraph.

The dilutive effect, if any, of outstanding options is reflected as additional share dilution in the computation of diluted earnings per share.

(v) New and Amended Accounting Standards and Interpretations Adopted by the Group

The Group has adopted all of the new or amended Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ('AASB') that are mandatory for the current reporting period.

None of these new or amended Accounting Standards and Interpretations has had a material impact on the Group's financial statements.

(w) New Accounting Standards and Interpretations for Application in Future Periods

Australian Accounting Standards and Interpretations that have recently been issued or amended but are not yet mandatory, have not been early adopted by the Group for the annual reporting period ended 31 December 2024.

These following most relevant, new or amended Accounting Standards and Interpretations are not expected to have a material impact on the consolidated entity's financial statements:

AASB S2 Climate-related Disclosures

Sets out disclosure requirements about an entity's climate-related risks and opportunities that could reasonably be expected to affect the entity's cash flows, access to finance or cost of capital over the short, medium or long term. The main climate-related financial disclosure requirements relate to governance, strategy, risk management, and metrics and targets, including information about scenario analysis and Scope 1, 2 and 3 greenhouse gas emissions and climate-related financial information.

The group currently expects to be a Group 3 entity under AASB S2, with mandatory application from 1 January 2027.

AASB 2023-5 Amendments to Australian Accounting Standards – Lack of Exchangeability

The Standard amends AASB 121 and AASB 1 to require entities to apply a consistent approach to determining whether a currency is exchangeable into another currency and the spot exchange rate to use when it is not exchangeable. It has mandatory application from 1 January 2025.

AASB 18 Presentation and Disclosure in Financial Statements

This will replace AASB 101 *Presentation of Financial Statements*. AASB 18 will better align the presentation of the statement of profit or loss to the categories in the statement of cash flows, require disclosure of management-defined performance measures and enhance the requirements for aggregation and disaggregation disclosure. It has mandatory

FOR THE YEAR ENDED 31 DECEMBER 2024 (CONTINUED)

application from 1 January 2027.

(x) Significant accounting judgements, estimates and assumptions

The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the reported amounts in the financial statements. Management continually evaluates its judgements and estimates in relation to assets, liabilities, contingent liabilities, revenue and expenses.

Management bases its judgements and estimates on historical experience and on other various factors it believes to be reasonable under the circumstances, the result of which form the basis of the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions and conditions.

Management has identified the following critical accounting policies for which significant judgements, estimates and assumptions are made. Actual results may differ from these estimates under different assumptions and conditions and may materially affect financial results or the financial position reported in future periods.

Further details of the nature of these assumptions and conditions may be found in the relevant notes to the financial statements.

Sale of goods

When recognising revenue in relation to sale of goods to customers, the key performance obligation of the Group is considered to be the point of delivery of the goods to the customer, as this is deemed to be the time that the customer obtains control of the promised goods and therefore the benefits of unimpeded access.

Contract Return Liability

The contract return liability requires a degree of estimation and judgement. It is measured based on projected historical data across market/ product range to estimate such returns at the time of sale based on an expected value methodology.

Allowance for expected credit losses

The allowance for expected credit losses assessment requires a degree of estimation and judgement. It is based on the lifetime expected credit loss, grouped based on days overdue, and makes assumptions to allocate an overall expected credit loss rate for customer. These assumptions include recent sales experience and historical collection rates.

Taxation

The Group's accounting policy for taxation requires management's judgement as to the types of arrangements considered to be a tax on income in contrast to an operating cost. Judgement is also required in assessing whether deferred tax assets and certain deferred tax liabilities are recognised on the statement of financial position. Deferred tax assets, including those arising from unrecouped tax losses, capital losses and temporary differences, are recognised only where it is considered more likely than not that they will be recovered, which is dependent on the generation of sufficient future taxable profits.

Judgements are also required about the application of income tax legislation. These judgements and assumptions are subject to risk and uncertainty, hence there is a possibility that changes in circumstances will alter expectations, which may impact the amount of deferred tax assets and deferred tax liabilities recognised on the statement of financial position and the amount of other tax losses and temporary differences not yet recognised. In such circumstances, some or all of the carrying amounts of recognised deferred tax assets and liabilities may require adjustment, resulting in a corresponding credit or charge to the *Consolidated Statement of Comprehensive Income*.

Share-based payment transactions

The Group measures the cost of equity-settled transactions with employees by reference to the fair value of the equity instruments at the date at which they are granted. The accounting estimates and assumptions relating to equity-settled share-based payments would have no impact on

the carrying amounts of assets and liabilities within the next annual reporting period but may impact expenses and equity.

The Group measures the cost of share-based payments at fair value at the grant date using the Black-Scholes formula taking into account the terms and conditions upon which the instruments were granted.

Estimation of useful lives of assets

The estimation of the useful lives of assets has been based on historical experience as well as manufacturers' warranties (for plant and equipment), lease terms (for leased equipment) and turnover policies (for motor vehicles). In addition, the condition of the assets is assessed at least once per year and considered against the remaining useful life. Adjustments to useful lives are made when considered necessary.

Inventory obsolescence

Inventories are stated at the lower of cost and net realisable value. The Directors assess slow moving or obsolete inventory on a regular basis and a provision is raised to write down inventory to net realisable value as described in note 2 (g).

(y) Comparative figures

When required by accounting standards, comparative figures have been adjusted to conform to changes in presentation for the current financial year.

(z) Rounding of amounts

The Group has applied the relief available to it under ASIC Corporations (Rounding in Financial/Director's Reports) Instrument 2016/191, dated 1 April 2016. Accordingly, amounts in the financial statements and Directors' report are rounded off to the nearest \$1,000.

FOR THE YEAR ENDED 31 DECEMBER 2024 (CONTINUED)

3 SEGMENT INFORMATION

The Group has identified its operating segments based on the internal reports that are reviewed and used by the Board of Directors (chief operating decision makers) in assessing performance and determining the allocation of resources. The Group is managed primarily on the basis of geographical market as the Group's risk and returns are affected predominantly by differences in the regulatory environment of the countries in which the Group operates. Products sold are similar across all countries, being vitamins and health supplements.

The operating businesses are organised and managed separately according to the location of the products sold, with each segment representing a strategic business unit that offers similar products in different geographical markets.

Geographical segment

The consolidated entity operates in the regions identified as Australia, Singapore, Malaysia, and Others. The Others segment is comprised of business operations in Thailand, Vietnam, Indonesia and China.

The Australia segment comprises of sale of Herbs of Gold range in Australia and exports into China.

The Singapore and Malaysia segment, comprise of Vitahealth and Herbs of Gold range in both countries and exports into other Asian markets.

The other market segment comprises of Vitahealth range into other Asia markets including Vietnam, Indonesia and Thailand.

The following tables present revenue and profit information and certain asset and liability information regarding geographical segments for the years ended 31 December 2024 and 31 December 2023.

	Australia \$'000	Singapore \$'000	Malaysia \$'000	Others \$'000	Corporate \$'000	Total \$'000
Year ended 31 December 2024						
Revenue						
Sales to external customers	44,443	7,571	25,661	1,830	-	79,505
Total segment revenue	44,443	7,571	25,661	1,830	-	79,505
Segment results						
Earnings before interest and tax	6,699	(353)	6,264	(454)	(345)	11,811
Net interest	(32)	105	(8)	2	763	830
Profit before income tax						12,641
Income tax expense						(3,862)
Net profit for the year						8,779
Assets and liabilities						
Segment assets	19,060	7,641	27,511	978	16,694	71,884
Total assets						71,884
Segment liabilities	7,359	2,536	8,935	320	459	19,609
Total liabilities						19,609
Other segment information						
Capital expenditure	(29)	(1,242)	(152)	(251)	-	(1,674)
Depreciation	(88)	(189)	(185)	(125)	-	(587)
Amortisation	-	-	(25)	-	-	(25)

The Group has no customer who contributed more than 10% of the Group's revenue in the year (2023: one). The revenue earned from this customer amounts to N/A (2023: \$12.4m). This customer is reported under the Australia segment.

FOR THE YEAR ENDED 31 DECEMBER 2024 (CONTINUED)

3. SEGMENT INFORMATION (CONTINUED)

Geographical segment (continued)

	Australia \$'000	Singapore \$'000	Malaysia \$'000	Others \$'000	Corporate \$'000	Total \$'000
Year ended 31 December 2023						
Revenue						
Sales to external customers	42,756	6,252	22,828	1,591	-	73,427
Total segment revenue	42,756	6,252	22,828	1,591	-	73,427
Segment results						
Earnings before interest and tax	6,237	(9)	5,736	167	(103)	12,028
Net interest	47	65	55	30	226	423
Profit before income tax						12,451
Income tax expense						(3,373)
Net profit for the year						9,078
Assets and liabilities						
Segment assets	17,459	7,032	18,825	1,528	14,963	59,807
Total assets						59,807
Segment liabilities	7,047	2,573	6,065	301	490	16,476
Total liabilities						16,476
Other segment information						
Capital expenditure	(93)	(502)	(107)	(1)	-	(703)
Depreciation	(106)	(102)	(160)	(127)	-	(495)
Amortisation	-	-	(10)	(7)	-	(17)

FOR THE YEAR ENDED 31 DECEMBER 2024 (CONTINUED)

4. REVENUE AND EXPENSES

	2024 \$'000	2023 \$'000
(a) Other loss		
Realised (loss) on foreign exchange	(23)	(180)
Unrealised gain (loss) on foreign exchange	97	(32)
Other income	81	29
	155	(183)
(b) Administrative expenses		
Legal and other professional fees	(556)	(483)
Consultants and subscriptions	(728)	(492)
(Allowance) Reversal for impairment loss	(143)	10
Wages, salaries and other employee expenses	(15,077)	(13,996)
Defined contribution superannuation expense	(1,537)	(1,272)
Travelling expenses	(785)	(587)
Share based payment expense	(435)	(684)
Depreciation	(587)	(495)
Amortisation	(25)	(17)
Other administrative expenses	(417)	(687)
	(20,290)	(18,703)
(c) Other expenses		
Product registration costs	(398)	(339)
	(398)	(339)
(d) Finance income		
Interest received - unrelated parties	1,039	558
	1,039	558
(e) Finance expenses		
Interest expense - unrelated parties	(46)	(60)
Bank charges	(163)	(75)
	(209)	(135)

FOR THE YEAR ENDED 31 DECEMBER 2024 (CONTINUED)

5. EARNINGS PER SHARE

Earnings per share (cents per share)

	2024	2023
- basic earnings per share	15.79	16.92
- diluted earnings per share	15.79	16.60

(a) Earnings used in calculating earnings per share

	2024 \$'000	2023 \$'000
Net profit attributable to equity holders from continuing operations	8,779	9,078
Loss attributable to non-controlling interest	5	2
Earnings used to calculate basic and dilutive earnings per share	8,784	9,080

(b) Weighted average number of shares

	2024 Number	2023 Number
Weighted average number of ordinary shares for basic earnings per share	55,619,763	53,666,979
Adjusted weighted average number of ordinary shares for diluted earnings per share. As of 31 December 2024, all the LTIP shares currently in issue are out of the money, and are therefore non-dilutive for this calculation. As at 31 December 2023, selected LTIP shares were classified as dilutive for purposes of this calculation as they were in the money.	55,619,763	54,691,979

FOR THE YEAR ENDED 31 DECEMBER 2024 (CONTINUED)

6. INCOME TAXES

(a) Income tax expense

	2024 \$'000	2023 \$'000
The major components of income tax expense are:		
Income Statement:		
<i>Current income tax</i>		
Current income tax charge	3,948	3,675
Prior year under provision	28	7
<i>Deferred income tax</i>		
Relating to origination and reversal of temporary differences	(114)	(309)
Income tax expense reported in the income statement	3,862	3,373

(b) A reconciliation between tax expense and the product of accounting profit before income tax multiplied by the Group's applicable income tax rate is as follows:

	2024 \$'000	2023 \$'000
Total accounting profit before income tax	12,641	12,451
At the parent entity's statutory income tax rate of 30.0% (2023: 30.0%)	3,792	3,735
Adjustment in respect of current income tax of previous year	28	7
Foreign tax rate adjustment	(402)	(386)
Share based payments	131	205
Other expenditure not allowable for income tax purposes	90	90
Deferred tax asset recognised during financial year	(114)	(309)
Tax losses and timing differences not brought to account	337	31
Income tax expense	3,862	3,373
The applicable weighted tax rates are as follows:	31%	27%

FOR THE YEAR ENDED 31 DECEMBER 2024 (CONTINUED)

6. INCOME TAXES (CONTINUED)

(c) Deferred income tax at 31 December relates to the following:

	2024 \$'000	2023 \$'000
Deferred tax assets		
Doubtful debts	155	155
Provision for sales returns/ stock obsolescence	1,300	1,136
Provision for annual leave	134	134
Provision for long service leave	192	158
Other provisions	834	739
Net deferred tax assets	2,615	2,322
Presented in the consolidated Statement of Financial Position as follows:		
Deferred tax assets	2,615	2,322
Deferred tax liabilities	-	-
	2,615	2,322

(d) Tax losses

The Group has carry forward tax losses of SGD \$15.8million (A\$18.7m) (2023: SGD \$15.8 million (A\$17.6m)) held within a wholly owned subsidiary, for which no deferred tax asset is brought to account. These losses are available indefinitely for offset against taxable income of the companies in which those losses arose subject to the meeting of the conditions required under the shareholders' continuity test. The benefit of these tax losses has not been brought to account as the probable recognition criteria has not been satisfied. Were these tax losses to be recognised, it would result in a deferred tax asset at the Singaporean company tax rate of 17%.

(e) Tax consolidation

(i) Members of the tax consolidated group and the tax sharing agreement

The Company is the head entity of the tax consolidated group comprising all the Australian wholly owned subsidiaries. The implementation date for the tax consolidated

group was for the tax period ended 30 June 2003. Members of the group have entered into a tax sharing agreement that provides for the allocation of income tax liabilities between the entities should the head entity default on its tax payment obligations. No amounts have been recognised in the financial statements in respect of this agreement on the basis that the possibility of default is remote.

Measurement method adopted under AASB 112 Tax Consolidation Accounting

The head entity and the controlled entities in the tax consolidated group continue to account for their own current and deferred tax amounts. Current and deferred tax amounts are measured in a systematic manner that is consistent with the broad principles in AASB 112 Income Taxes.

The current and deferred tax amounts of the members of the tax consolidated group are recognised in the separate financial statements of the members of the tax consolidated group using a "Stand-Alone Taxpayer" approach by reference to the

carrying amounts of assets and liabilities in the separate financial statements of each entity and the tax values applying under consolidation.

Any current tax Australian liabilities (or assets) and deferred tax assets arising from unused tax losses of the subsidiaries are assumed by the head entity in the tax consolidated group and are recognised as amounts receivable from (payable to) other entities in the tax consolidated group. Any difference between these amounts is recognised by the head entity as an equity contribution or distribution.

The Company recognises deferred tax assets arising from unused tax losses of the tax consolidated group to the extent that it is probable that future taxable profits of the tax consolidated group will be available against which the asset can be utilised. Any subsequent period adjustments to deferred tax assets arising from unused tax losses as a result of revised assessments of the probability of recoverability is recognised by the head entity only.

FOR THE YEAR ENDED 31 DECEMBER 2024 (CONTINUED)

6. INCOME TAXES (CONTINUED)

Nature of the tax funding agreement

Members of the tax consolidated group have entered into a tax funding agreement, which sets out the funding obligations of members of the tax consolidated group. Payments required to / (from) head entity are equal to the current tax liability / (assets) assumed from the members of the tax consolidated group. The inter-entity receivable (payable) is at call.

Tax consolidation contributions / (distributions)

The Company has recognised the following amount as tax-consolidation contribution adjustments:

	2024 \$'000	2023 \$'000
Total increase in intercompany receivable of Vita Life Sciences Limited	2,066	2,139

7. CASH AND CASH EQUIVALENTS

	2024 \$'000	2023 \$'000
Cash at bank and in hand (a)	7,104	5,427
Short term deposit (b)	21,497	19,203
Total cash and cash equivalents	28,601	24,630

(a) Cash at bank earns interest at floating rates based on daily bank deposit rates.

(b) Short term deposit earns interest at the respective short-term deposit rates.

(c) The fair value of cash equivalents for the Group is as stated above.

FOR THE YEAR ENDED 31 DECEMBER 2024 (CONTINUED)

7. CASH AND CASH EQUIVALENTS (CONTINUED)

(d) Reconciliation of net profit after tax to net cash flows from operations

	2024 \$'000	2023 \$'000
Net profit after tax	8,779	9,078
Adjustments for non-cash income and expense items:		
Depreciation and Fair value adjustment	587	830
Amortisation	25	17
Shared based expense	435	684
Allowance/(Reversal of) for impairment loss	143	(10)
	9,969	10,599
Increase/decrease in assets and liabilities:		
(Increase) Decrease in inventories	(5,446)	4,257
Increase in receivables	(782)	(2,238)
Increase in other assets	(408)	(209)
Increase in deferred tax balances	(293)	(162)
Increase in current income tax payable	507	37
Increase in trade and other payables	2,064	985
Increase in other liabilities	432	372
Effect of foreign exchange translation of assets and liabilities	112	(659)
	6,155	12,982
Net cash provided by operating activities		

Non-cash financing and investing activities:

During the year ended 31 December 2024, 875,000 (2023: Nil) new Long Term Incentive Plan (LTIP) Shares were issued. Refer to Note 23 for further details.

FOR THE YEAR ENDED 31 DECEMBER 2024 (CONTINUED)

8. TRADE AND OTHER RECEIVABLES

	2024 \$'000	2023 \$'000
Current		
Trade receivables, third parties	11,897	10,749
Allowance for expected credit losses	(190)	(47)
	<u>11,707</u>	<u>10,702</u>
Other receivables:		
Other receivables (a)	244	483
Net tax receivable	48	30
	<u>11,999</u>	<u>11,215</u>

(a) Other receivables are non-interest bearing and have repayment terms between 30 to 90 days. It is expected that these other balances will be received when due.

(b) Fair value

The carrying value for trade and other receivables is assumed to approximate their fair value. The maximum exposure to credit risk is the fair value of receivables.

(c) Foreign exchange risk

Details regarding foreign exchange risks exposure are disclosed in Note 22.

FOR THE YEAR ENDED 31 DECEMBER 2024 (CONTINUED)

9. INVENTORIES

	2024 \$'000	2023 \$'000
Current		
Raw materials at cost	7,451	4,218
Finished goods at lower of cost and net realisable value	10,268	8,197
Less: Provision for stock obsolescence	(1,120)	(1,262)
	16,599	11,153

10. OTHER ASSETS

	2024 \$'000	2023 \$'000
Current		
Prepayments	768	587
Sundry deposits	931	704
	1,699	1,291

FOR THE YEAR ENDED 31 DECEMBER 2024 (CONTINUED)

11. PROPERTY, PLANT AND EQUIPMENT

	Land and Building \$'000	Leasehold Improvements \$'000	Plant and Equipment \$'000	Leased Plant and Equipment \$'000	Right of Use-Building \$'000	Right of Use-Plant and Equipment \$'000	Capital Work-In-Progress \$'000	Total \$'000
Year ended 31 December 2024								
At 1 January 2024 net of accumulated depreciation and impairment	7,947	24	375	-	288	56	480	9,170
Additions	-	251	740	233	450	-	-	1,674
Disposal/ Reclassification	-	-	(543)	-	(34)	-	(480)	(1,057)
Depreciation / amortisation for the year	(69)	(62)	(165)	(34)	(239)	(18)	-	(587)
Exchange differences	1,033	1	92	(2)	3	2	-	1,129
At 31 December 2024 net of accumulated depreciation, adjustments and impairment	8,911	214	499	197	468	40	-	10,329
At 31 December 2024								
Cost/ revalued	9,622	298	2,259	401	1,054	93	-	13,727
Accumulated depreciation and impairment	(711)	(84)	(1,760)	(204)	(586)	(53)	-	(3,398)
Net carrying amount	8,911	214	499	197	468	40	-	10,329

The Group leases office premises and warehouse facilities under various agreements of between two and three years and, in some cases with options to extend. The leases have various escalation clauses. On renewal, the terms of the leases are renegotiated. The Group also leases equipment under agreements of between three and five years.

(a) Fair Value Measurement

In December 2023, the Company engaged a professional independent valuer, to determine the fair value of its land and building, which was based on recent transactions for similar assets within the same location. i.e. the Comparison Approach. As a check, the Cost Approach based on the aggregate amount of the value of the land component and gross replacement cost of the building and other site improvements allowing for depreciation was used.

	2024 \$'000	2023 \$'000
Gain on Revaluation as recognised in the Consolidated Statement of Comprehensive Income	-	335
Gain on Revaluation as recognised in Revaluation Reserve	-	534
	-	869

FOR THE YEAR ENDED 31 DECEMBER 2024 (CONTINUED)

11. PROPERTY, PLANT AND EQUIPMENT (CONTINUED)

	Land and Building	Leasehold Improvements	Plant and Equipment	Leased Plant and Equipment	Right of Use-Building	Right of Use-Plant and Equipment	Capital Work-In-Progress	Total
	\$'000	\$'000	\$'000	\$'000	\$'000	\$'000	\$'000	\$'000
Year ended 31 December 2023								
At 1 January 2023 net of accumulated depreciation and impairment	7,413	30	457	4	504	64	-	8,472
Additions	89	-	91	-	43	-	480	703
Disposal	-	-	-	-	-	(2)	-	(2)
Depreciation / amortisation for the year	(69)	(3)	(154)	(3)	(256)	(10)	-	(495)
Exchange differences	(355)	(3)	(19)	(1)	(3)	4	-	(377)
Fair value adjustments	869	-	-	-	-	-	-	869
At 31 December 2023 net of accumulated depreciation, adjustments and impairment	7,947	24	375	-	288	56	480	9,170
At 31 December 2023								
Cost/ revalued	8,509	124	1,875	161	882	89	480	12,120
Accumulated depreciation and impairment	(562)	(100)	(1,500)	(161)	(594)	(33)	-	(2,950)
Net carrying amount	7,947	24	375	-	288	56	480	9,170

FOR THE YEAR ENDED 31 DECEMBER 2024 (CONTINUED)

12. TRADE AND OTHER PAYABLES

	2024 \$'000	2023 \$'000
Current		
Trade payables (a)	5,576	5,579
Net tax payable	986	151
Other payables and accruals	5,183	3,951
	11,745	9,681

(a) Trade payables are non-interest bearing and are normally settled within 90-day terms. Other payables are non-interest bearing and have an average term of 3 months.

(b) Fair value

Due to the short term nature of these payables, their carrying values are assumed to approximate their fair value.

(c) Foreign exchange and liquidity risks

Information regarding foreign exchange and liquidity risks are set out in Note 22.

FOR THE YEAR ENDED 31 DECEMBER 2024 (CONTINUED)

13. EMPLOYEE ENTITLEMENTS

Provision is made for employee benefits accumulated as a result of employees rendering services up to the reporting date. These benefits include wages and salaries, annual leave and long service leave.

	Employee Entitlements \$'000
Balance at 1 January 2024	2,239
Charged during the year	1,158
Used during the year	(1,434)
Foreign exchange difference	(2)
Balance at 31 December 2024	1,961
At 31 December 2024	
Current	1,840
Non-Current	121
	1,961
At 31 December 2023	
Current	2,155
Non-Current	84
	2,239

14. CONTRACT RETURN LIABILITY

The Contract Return Liability is to account for the right of return assets and refund liabilities.

	2024 \$'000	2023 \$'000
Balance at 1 January	4,095	3,899
Charged in the year	2,590	2,040
Used during year	(2,308)	(1,741)
Foreign Exchange Difference	428	(103)
Balance at 31 December	4,805	4,095

FOR THE YEAR ENDED 31 DECEMBER 2024 (CONTINUED)

15. LEASE LIABILITY

	2024 \$'000	2023 \$'000
At 31 December		
Current	303	211
Non-Current	214	176
	517	387

The lease liabilities are secured by the related underlying assets. The undiscounted maturity analysis of lease liabilities as at 31 December 2024 is as follows:

Minimum lease payments due within:	1 Year \$'000	2-3 Years \$'000	4-5 Years \$'000	Total \$'000
31 December 2024				
Lease Payments	327	133	108	568
Finance charges	(24)	(20)	(7)	(51)
Lease Liability	303	113	101	517

16. CONTRIBUTED EQUITY

	2024 Number	2023 Number	2024 \$	2023 \$
Issued and paid up capital				
Ordinary shares	56,560,582	56,400,137	45,030,261	42,566,853
Ordinary shares				
Balance at beginning of the year	56,400,137	56,526,612	42,566,853	41,904,024
Share buy back (a)	(714,555)	(126,475)	(1,392,592)	(208,421)
Payment of loan for shares to Employees/ Directors (b)	-	-	3,856,000	871,250
Issue of shares to Employees and Directors (b)	875,000	-	-	-
Balance at end of the year	56,560,582	56,400,137	45,030,261	42,566,853

Ordinary shares participate in dividends and the proceeds on winding-up of the parent entity in proportion to the number of shares held.

(a) Share Buy-Back

A total of 714,555 (2023:126,475) ordinary shares were bought back for year ended 31 December 2024 at a total cost of \$1,392,592 (2023: \$208,421).

FOR THE YEAR ENDED 31 DECEMBER 2024 (CONTINUED)

16. CONTRIBUTED EQUITY (CONTINUED)

(b) Issue of Long Term Incentive Plan Shares to key executives

In 2024, the Company recognised net expense of \$434,635 (2023: \$683,901) in the income statement with a corresponding increase (2023: increase) in employee share based payment reserve.

On 27 Sep 2024, the Company issued 875,000 new shares at a total price of \$2,012,500 to a director and employees under the Company's Long Term Incentive Plans (LTIP).

A sum of \$3,856,000 (2023: \$871,250) LTIP share scheme loan was fully repaid during the year.

(c) Capital management

When managing capital, management's objective is to ensure the Company continues as a going concern as well as to maintain optimal returns for shareholders and benefits for other stakeholders. Management also aims to maintain a capital structure that ensures the lowest cost of capital available to the entity.

Management constantly assesses the capital structure to take advantage of favourable costs of capital and / or high returns on assets. As the market is continuously changing, management may issue dividends to shareholders, return capital to shareholders, issue new shares, increase the short or long term borrowings or sell assets to reduce borrowings.

(d) Dividends

The Directors declared a fully franked interim dividend of 3.50 cents per share and a fully franked final dividend of 6.50 cents per share in respect of the financial year ended 31 December 2024 (2023: interim dividend of 3.25 cents fully franked and a final dividend of 6.00 cents fully franked).

The final dividend of 6.50 cents per share has not been recognised in these consolidated financial statements as it was declared subsequent to 31 December 2024.

	2024 Cents per Share	2023 Cents per Share	2024 \$'000	2023 \$'000
Fully paid ordinary shares				
Final dividend for the previous financial year				
- Full franking credits attached	6.00	3.25	3,263	1,749
Interim dividend for the financial year				
- Full franking credits attached	3.50	3.00	1,906	1,618
	9.50	6.25	5,169	3,367

FOR THE YEAR ENDED 31 DECEMBER 2024 (CONTINUED)

17. NET TANGIBLE ASSETS PER SHARE

	2024 \$	2023 \$
Net assets per share	0.92	0.77
Net tangible assets per share	0.88	0.73
	Number	Number
Number of ordinary shares for net assets per share	56,560,582	56,400,137

18. RESERVES

(a) Employee share based payments reserve

The employee share based payments reserve is used to record the value of share based payments provided to employees, including Key Management Personnel, as part of their remuneration.

(b) Foreign currency translation reserve

The foreign currency translation reserve is used to record exchange differences arising from the translation of the financial statements of foreign subsidiaries.

19. RELATED PARTY DISCLOSURE

(a) Key Management Personnel

Details relating to Key Management Personnel, including remuneration paid, are included in note 20.

(b) Ultimate holding company

Vita Life Sciences Limited is the ultimate holding company for the Group.

(c) Transactions with related parties

The total amount of transactions that were entered into with related parties for the relevant financial year were:

- i. Land Real Pty Ltd, a company in which Mr Henry Townsing is a Director and therefore a related party, was paid \$900 for storage charges (2023: \$1,200) during the financial year.

Terms and conditions of transactions with related parties

Purchases from related parties are made at arm's length transactions both at normal market prices and on normal commercial terms.

Outstanding related party payables at year-end are unsecured, interest free and settlement occurs in cash.

FOR THE YEAR ENDED 31 DECEMBER 2024 (CONTINUED)

19. RELATED PARTY DISCLOSURE (CONTINUED)

(d) Subsidiaries

The consolidated financial statements include the financial statements of Vita Life Sciences Limited and the subsidiaries listed in the following table. Balances and transactions between the Company and its subsidiaries, which are related parties of the Company have been eliminated on consolidation and are not disclosed in this note.

Name	Place of Incorporation	Percentage of Equity Interest	
		2024 %	2023 %
Herbs of Gold Pty Limited	Australia	100	100
Herbs of Gold (Shanghai) Co. Limited	People's Republic of China	100	100
VitaHealth Laboratories Australia Pty Limited	Australia	100	100
Vita Institute of Health Pty Ltd	Australia	100	100
VitaHealth Australia Pty Ltd	Australia	100	100
Vita Corporation Pte Limited	Singapore	100	100
Herbs of Gold (S) Pte Ltd	Singapore	100	100
Vpacks (S) Pte Ltd	Singapore	100	100
VitaHealth Laboratories (HK) Limited	Hong Kong	100	100
Vita Healthcare Asia Pacific Sdn Bhd	Malaysia	100	100
VitaHealth Malaysia Sdn Bhd	Malaysia	100	100
VitaHealth Biotech Sdn Bhd	Malaysia	100	100
Vita Lifesciences Sdn Bhd	Malaysia	100	100
Vita Science Sdn Bhd	Malaysia	100	100
Herbs of Gold Sdn Bhd	Malaysia	100	100
VitaHealth Asia Pacific (S) Pte Limited	Singapore	100	100
Vita Life Sciences (S) Pte Limited	Singapore	100	100
VitaHealth IP Pte Limited	Singapore	100	100
Vita Life Sciences (Thailand) Co. Ltd	Thailand	49	49
VitaHealth (Thailand) Co. Ltd	Thailand	74	74
Vita Health Vietnam Company Limited	Vietnam	100	100
Herbs of Gold Vietnam Company Limited	Vietnam	100	100
Pharma Direct Sdn Bhd	Malaysia	100	100
PT. Vita Health Indonesia	Indonesia	100	100
Lovin Pharma International Limited	Ireland	100	100

FOR THE YEAR ENDED 31 DECEMBER 2024 (CONTINUED)

20. DIRECTORS AND KEY MANAGEMENT PERSONNEL REMUNERATION

Information regarding individual Directors and executives' compensation and some equity instruments disclosures as required by Corporations Regulation 2M.3.03 are provided in the Remuneration Report section of the Directors' Report.

Summary of remuneration of Directors and Key Management Personnel (KMP):

	Short term salary, incentive, fees and leave \$	Post- employment benefits \$	Other long term benefits \$	Share based payment expense \$	Total \$
2024	1,990,829	140,176	20,671	405,835	2,557,511
2023	1,720,802	112,576	19,954	650,953	2,504,285

Short-term salary, incentive, fees and leave

These amounts include fees and benefits paid to the non-executive Chair and non-executive Directors as well as salary, paid leave benefits, fringe benefits and cash bonuses awarded to executive Directors and other KMP.

Post-employment benefits

These amounts are the current-year's estimated cost of providing for superannuation contributions made during the year.

Other long term benefits

These amounts represent long service leave benefits accruing during the year.

Share based payment expense

These amounts represent the expense related to the participation of KMP in equity-settled benefit schemes as measured by the fair value of the options, rights and shares granted on grant date.

Further information in relation to KMP remuneration can be found in the Directors' Report.

FOR THE YEAR ENDED 31 DECEMBER 2024 (CONTINUED)

21. PARENT ENTITY DISCLOSURES

Financial Position as at 31 December	2024 \$'000	2023 \$'000
ASSETS		
Current Assets	16,532	14,763
Non - Current Assets	10,392	10,392
Total Assets	26,924	25,155
LIABILITIES		
Current Liabilities	8,110	6,034
Non-Current Liabilities	21,901	22,526
Total Liabilities	30,011	28,560
Equity		
Issued capital	45,030	42,567
Accumulated losses	(51,862)	(49,282)
Employee share based payments and share option reserve	3,745	3,310
Parent entity interest	(3,087)	(3,405)
Non-controlling Interest	-	-
Total Equity	(3,087)	(3,405)
Financial performance for the year ended 31 December		
Profit for the year	2,535	9,878
Other comprehensive income	-	-
Total comprehensive income for the year	2,535	9,878

The Parent Entity (Vita Life Sciences Limited) has a net current asset surplus at 31 December 2024, consistent with that at 31 December 2023. The Parent Entity is able to call on the resources of the Vita Life Sciences Group as required, and as such the financial statements of the Parent Entity are prepared on a going concern basis.

FOR THE YEAR ENDED 31 DECEMBER 2024 (CONTINUED)

22. FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES

The Group's principal financial instruments comprise receivables, payables, finance leases, cash and short-term deposits.

It is, and has been throughout the period under review, the Group's policy that no trading in financial instruments shall be undertaken.

The main risks arising from the Group's financial instruments are interest rate risk and credit risk. The Group manages these risks in accordance with the Group's financial risk management policy. The objective of this policy is to support the delivery of the Group's financial targets whilst protecting future financial security. The Group uses different methods to measure and manage different types of risks to which it is exposed. These include monitoring levels of exposure to interest rate movements. Ageing analyses and monitoring of specific credit allowances are undertaken to manage credit risk.

The Board reviews and agrees policies for managing each of these risks and they are summarised below.

Risk exposures and responses

Interest rate risk

The Group's exposure to market risk for changes in interest rates relates primarily to the Group's funds. The Company has no external borrowings.

At balance date, the Group had the following financial assets exposed to variable interest rate risk:

	2024 \$'000	2023 \$'000
Financial assets		
Cash at bank and in hand	7,104	5,427
Short term deposit	21,497	19,203
	28,601	24,630

As the Company has no borrowings, any interest rate risk is in interest income arising from cash assets.

The following sensitivity analysis is based on the interest rate risk exposure in existence at the Statement of Financial Position date.

At 31 December 2024, if interest rates had moved, as illustrated in the table below, with all other variables held constant, pre-tax profit would have been affected as follows:

	2024 \$'000	2023 \$'000
Judgements of reasonably possible movements:		
Profit before income tax		
+ 1.0%	286	246
- 1.0%	(286)	(246)

The movement in profit is due to possible higher or lower income from cash balances arising from changes in interest rates.

FOR THE YEAR ENDED 31 DECEMBER 2024 (CONTINUED)

22. FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES (CONTINUED)

Credit risk

Credit risk arises mainly from the risk of counterparties defaulting on the terms of their agreements. The carrying amounts of the following assets represent the Group's maximum exposure to credit risk in relation to financial assets:

	2024 \$'000	2023 \$'000
Financial assets		
Cash at bank and in hand (a)	7,104	5,427
Short term deposit (a)	21,497	19,203
Trade and other receivable (b)	11,999	11,215
	40,600	35,845

(a) Cash at bank and short term deposit

The Group mitigates credit risk on cash at bank and short term deposit by dealing with only government regulated banks.

(b) Trade and other receivables

The Group trades only with recognised, creditworthy third parties. It is the Group's policy that all customers who wish to trade on credit terms are subject to credit verification procedures. In addition, receivable balances are monitored on an ongoing basis with the result that the Group's exposure to bad debts is not significant.

For transactions that are not denominated in the measurement currency of the relevant operating unit, the Group does not offer credit terms without the specific approval of the Managing Director or Executive Director of that business.

Exposure at balance date is addressed in each application note. The Group does not have any assets which are past due at balance date.

Foreign currency risk

As a result of significant operations in the Asian countries, the Group's statement of financial position can be affected significantly by movements in the exchange rates of these countries. The Group does not hedge this exposure. The Group also has transactional currency exposures. Such exposure arises from sales or purchases by an operating entity in currencies other than the functional currency.

FOR THE YEAR ENDED 31 DECEMBER 2024 (CONTINUED)

22. FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES (CONTINUED)

Foreign currency risk (continued)

At 31 December, the Group had the following exposure to foreign currencies:

	2024 \$'000	2023 \$'000
Financial assets		
Cash and cash equivalents		
Singapore Dollar (SGD)	4,510	4,927
Malaysia Ringgit (RM)	4,050	2,474
Chinese Yuan Renminbi (RMB)	262	607
Indonesian Rupiah (IDR)	50	30
Vietnamese Dong (VND)	368	367
Thai Baht (THB)	2	6
Trade and other receivables		
Singaporean Dollar (SGD)	595	604
Malaysian Ringgit (RM)	5,890	6,193
Hong Kong Dollar (HKD)	2	-
Indonesian Rupiah (IDR)	9	8
Vietnamese Dong (VND)	185	124
Thai Baht (THB)	241	218
	16,162	15,558
Financial liabilities		
Trade and other payables		
Singapore Dollar (SGD)	676	559
Malaysia Ringgit (RM)	4,976	3,236
Hong Kong Dollar (HKD)	5	4
Chinese Yuan Renminbi (RMB)	63	42
Indonesian Rupiah (IDR)	7	14
Vietnamese Dong (VND)	289	258
Thai Baht (THB)	3	3
	6,019	4,116
Net exposure	10,143	11,442

FOR THE YEAR ENDED 31 DECEMBER 2024 (CONTINUED)

22. FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES (CONTINUED)

Price risk

The Group's direct exposure to commodity price risk is minimal.

Liquidity risk

The Group's objective is to maintain a balance between continuity of funding and flexibility through the use of loans.

The table below reflects all contractually fixed pay-offs for settlement of financial liabilities and collection of financial assets. Trade payables and other financial liabilities generally originate from the financing of assets used in our ongoing operations such as investment in working capital (inventories, trade receivables and investment in property, plant and equipment). These assets are considered in the Group's overall liquidity risk. To monitor existing financial assets and liabilities as well as to enable an effective controlling of future risks, the Group monitors its expected settlement of financial assets and liabilities on an ongoing basis.

	Weighted average interest rate	Interest Free \$'000	Floating interest rate \$'000	Fixed interest maturing 1 year or less \$'000	Fixed interest maturing 1 to 5 years \$'000	Total \$'000
2024						
Financial Assets						
Cash assets - see Note 7	4.4%	-	7,104	21,497	-	28,601
Trade and other receivables - see Note 8	n/a	11,999	-	-	-	11,999
		11,999	7,104	21,497	-	40,600
Financial Liabilities						
Trade and other payables - see Note 12	n/a	11,745	-	-	-	11,745
		11,745	-	-	-	11,745
2023						
Financial Assets						
Cash assets - see Note 7	4.7%	-	5,427	19,203	-	24,630
Trade and other receivables - see Note 8	n/a	11,215	-	-	-	11,215
		11,215	5,427	19,203	-	35,845
Financial Liabilities						
Trade and other payables - see Note 12	n/a	9,681	-	-	-	9,681
		9,681	-	-	-	9,681

Fair value

All of the Group's financial instruments recognised in the Consolidated Statement of Financial Position have been assessed as at fair values.

FOR THE YEAR ENDED 31 DECEMBER 2024 (CONTINUED)

23. SHARE BASED PAYMENT PLANS

(a) Recognised share based payment expenses

Expense arising from equity settled share based payment transactions:

	2024 \$'000	2023 \$'000
Share based expense on Long Term Incentive Plan	435	684

The share-based payment plans are described below.

(b) Types of share based payment plans

(i) Shares

Long Term Incentive Plan ("Plan") Shares are granted to certain executive Directors and certain employees.

In valuing transactions settled by way of issue of shares, no account is taken of any performance conditions, other than market conditions linked to the price of the shares of Vita Life Sciences Limited.

All Plan Shares issued have market performance conditions and certain performance conditions ("Hurdles") so as to align shareholder return and reward for the Company's selected management and staff ("Participants").

The Board has residual discretion to accelerate vesting i.e. reduce or waive the Hurdles and exercise of Plan Shares in the event of a takeover or merger or any other circumstance in accordance with the terms of the Plan.

Plan Shares in relation to which Hurdles have not been satisfied i.e. that do not vest will lapse and will not be able to be exercised, except in the circumstances described below.

Plan Shares which have not vested will lapse where a Participant ceases employment with the Company other than on retirement, redundancy, death or total and permanent disablement or unless as otherwise determined by the Board in its absolute discretion.

Where a Participant has ceased employment with the Company as a result of resignation, retirement, redundancy, death or total and permanent disablement prior to the end of a performance period, only Plan Shares that have vested may be retained by the Participant on a pro-rata basis. If a Plan share holder ceases employment for any reasons mentioned above prior to the first anniversary of the grant date, the Participant forfeits all entitlement to Shares.

(ii) Plan shares issued in 2024

In 2024, the Company at the AGM, approved loans to the Managing Director, Mr Andrew O'Keefe totalling \$690,000 in order for Mr O'Keefe to purchase a total of 300,000 new shares under the Company's Plan. During the year, the Company also approved loans to selected employees totalling \$1,322,500 in order for them to purchase a total of 575,000 shares under the Plan.

(iii) Plan shares issued in 2022

In 2022, the Company at the AGM, approved loans to the Managing Director, Mr Andrew O'Keefe totalling \$945,000 in order for Mr O'Keefe to purchase a total of 1,000,000 new shares under the Company's Plan. The Company at the AGM, also approved loans to Mr Henry Townsing totalling \$567,000 in order for him to purchase a total of 300,000 shares under the Plan. During the year, the Company also approved loans to selected employees totalling \$1,370,250 in order for them to purchase a total of 725,000 shares under the Plan.

(iv) Plan shares issued in 2021

In 2021, the Company at the AGM, approved loans to the Managing Director, Mr Andrew O'Keefe totalling \$900,000 in order for Mr O'Keefe to purchase a total of 1,000,000 new shares under the Company's Plan. During the year, the Company also approved loans to selected employees totalling \$945,000 in order for them to purchase a total of 1,050,000 shares under the Plan.

FOR THE YEAR ENDED 31 DECEMBER 2024 (CONTINUED)

23. SHARE BASED PAYMENT PLANS (CONTINUED)

(v) Plan Shares

AASB 2 Share Based Payments requires that the benefit to an employee arising from an employee share scheme such as the Vita Life Sciences Long Term Incentive Plan be treated as an expense over the vesting period. All of the above issues of Plan shares have been treated as Plan Share Options (“implied options”) in accordance with AASB 2. The employee benefit is deemed to be the fair value of the implied option arising from the Plan. Consequently, the value of the discount which has been determined using the Black Scholes option pricing model will be charged to the Statement of Comprehensive Income and credited to the Employee Share Based Payments Reserve over the vesting period.

Where employee shares are issued under a non-recourse loan payment plan, the loan assets and the increments to Contributed Equity are not recognised at grant date but rather the increments to Contributed Equity are recognised when the share loans are settled by the relevant employees.

The following table illustrates the number (No.) and weighted average exercise price (WAEP) of, and movements in Plan Shares during the year:

	2024 No.	2023 No.	2024 WAEP	2023 WAEP
Outstanding at the beginning of the year	2,550,000	3,575,000	1.51	1.32
Granted during the year - b(ii)	875,000	-	2.30	-
Exercised during the year-b(iii) & b (iv)	(2,550,000)	(1,025,000)	(1.51)	(0.85)
Outstanding at the end of the year	875,000	2,550,000	2.30	1.51

(v) Range of exercise price, weighted average remaining contractual life, weighted average fair value and weighted average value of share price at date of exercise of Plan Shares and unlisted Share Options.

The range of exercise prices for Plan Shares outstanding at the end of the financial year was \$2.30 (2023: \$0.95- \$1.89).

The weighted average remaining contractual life for the Plan Shares outstanding at the end of the financial year was 1.5 years (2023: 0.5 years).

2,550,000 plan shares (2023: 1,025,000) were exercised with the respective loan fully repaid, during the year.

FOR THE YEAR ENDED 31 DECEMBER 2024 (CONTINUED)

23. SHARE BASED PAYMENT PLANS (CONTINUED)

(vi) Implied option and share options pricing

The following assumptions were used to derive a value for the implied options granted using the Black Scholes Option model as at the grant date, taking into account the terms and conditions upon which the Plan Shares were granted:

Plan Shares issued in 2024	
No. of shares issued - b (ii)	875,000
Exercise price per implied option	2.30
Dividend yield	-
Expected annual volatility	36.80%
Risk-free interest rate (p.a.)	3.88%
Expected life of implied option (Years)	2.2
Fair value per implied option	\$0.58
Exercise price per implied option	\$2.30
Share price at grant date	\$2.31
Model used	Black Scholes

In respect of the implied options arising from the Shares granted in 2024, the expected volatility was determined using historic data over a 1-year period from Apr 2023 to Apr 2024.

FOR THE YEAR ENDED 31 DECEMBER 2024 (CONTINUED)

24. SUBSEQUENT EVENTS AFTER BALANCE SHEET DATE

Dividends

On 24 February 2025, the Directors announced a final fully franked dividend of 6.50 cents per share totalling \$3,619,563 in respect of the financial year ended 31 December 2024 (2023: fully franked dividend of 6.00 cents per share totalling \$3,321,008), payable on 11 April 2025. A fully franked interim dividend of 3.50 cents per share was paid on 4 October 2024 (2023: fully franked interim dividend of 3.00 cents per share).

Office Lease

A new office lease was entered into by Herbs of Gold Pty Ltd for a period of 5 years, prior to 31 December 2024, but effective from May 2025. The asset and liability was not recorded in the books as at 31 December 2024 due to various conditions precedent.

Other than the above, no matters or circumstances have arisen since the end of the financial year which significantly affected or may significantly affect the operations of the Group, financial position of the Group or the state of affairs of the Group in future financial periods.

25. AUDITOR'S REMUNERATION

The auditor of Vita Life Sciences Limited is Nexia Sydney Audit Pty Limited.

	2024 \$'000	2023 \$'000
Amount receivable or due and receivable by the auditor of the parent entity:		
An audit or review of the financial report of the entity and any other entity in the consolidated group	130	118
Other services in relation to the entity and any other entity in the consolidated group provided by associate firm of auditor – tax compliance services	26	20
	156	138
Amount receivable or due and receivable by other auditors:		
– audit or review of the financial reports of controlled entities	134	129
	134	267

26. CONTINGENT ASSETS AND LIABILITIES

The Group has no contingent assets or liabilities at 31 December 2024 (2023: \$Nil).

27. CAPITAL COMMITMENTS

The Group has no capital commitments as at 31 December 2024 except as stated below (2023: \$Nil).

Capital Commitments **2025**

Committed at the reporting date but not recognised as liabilities payable:

Lease liability/ROU Asset

Total future lease payments: \$2,123,198

Lease liability at initial recognition: \$1,898,537

FOR THE YEAR ENDED 31 DECEMBER 2024

CONSOLIDATED ENTITY DISCLOSURE STATEMENT

The consolidated entity disclosure statement (CEDs) has been prepared in accordance with the Corporations Act 2001 and includes information for each entity that was part of the consolidated entity as at the end of the financial year in accordance with AASB 10 Consolidated Financial Statements.

Name of Entity (1)	Country of Incorporation	Ownership interest held by the Group (%)	Australian or foreign tax resident	Foreign tax resident jurisdiction
Vita Life Sciences Limited	Australia	N/A	Australian	N/A
Herbs of Gold Pty Limited	Australia	100	Australian	N/A
Herbs of Gold (Shanghai) Co. Limited	People's Republic of China	100	Foreign	People's Republic of China
VitaHealth Laboratories Australia Pty Limited	Australia	100	Australian	N/A
Vita Institute of Health Pty Ltd	Australia	100	Australian	N/A
VitaHealth Australia Pty Ltd	Australia	100	Australian	N/A
Vita Corporation Pte Limited	Singapore	100	Foreign	Singapore
Herbs of Gold (S) Pte Ltd	Singapore	100	Foreign	Singapore
Vpacks (S) Pte Ltd	Singapore	100	Foreign	Singapore
VitaHealth Laboratories (HK) Limited	Hong Kong	100	Foreign	Hong Kong
Vita Healthcare Asia Pacific Sdn Bhd	Malaysia	100	Foreign	Malaysia
VitaHealth Malaysia Sdn Bhd	Malaysia	100	Foreign	Malaysia
VitaHealth Biotech Sdn Bhd	Malaysia	100	Foreign	Malaysia
Vita Lifesciences Sdn Bhd	Malaysia	100	Foreign	Malaysia
Vita Science Sdn Bhd	Malaysia	100	Foreign	Malaysia
Herbs of Gold Sdn Bhd	Malaysia	100	Foreign	Malaysia
Pharma Direct Sdn Bhd	Malaysia	100	Foreign	Malaysia
VitaHealth Asia Pacific (S) Pte Limited	Singapore	100	Foreign	Singapore
Vita Life Sciences (S) Pte Limited	Singapore	100	Foreign	Singapore
VitaHealth IP Pte Limited	Singapore	100	Foreign	Singapore
Vita Life Sciences (Thailand) Co. Ltd	Thailand	49	Foreign	Thailand
VitaHealth (Thailand) Co. Ltd	Thailand	74	Foreign	Thailand
Vita Health Vietnam Company Limited	Vietnam	100	Foreign	Vietnam
Herbs of Gold Vietnam Company Limited	Vietnam	100	Foreign	Vietnam
PT. Vita Health Indonesia	Indonesia	100	Foreign	Indonesia
Lovin Pharma International Limited	Ireland	100	Foreign	Ireland

FOR THE YEAR ENDED 31 DECEMBER 2024 (CONTINUED)

CONSOLIDATED ENTITY DISCLOSURE STATEMENT (CONTINUED)

(1) All entities are corporate entities

Determination of tax residency

Section 295 (3A)(vi) of the Corporations Act 2001 defines tax residency as having the meaning in the Income Tax Assessment Act 1997. The determination of tax residency involves judgement as it can be fact dependent and subject to interpretation, requiring consideration of matters such as location of central management and control or place of effective management.

The rules and guidance in respect of tax residency have been applied in good faith. In determining tax residency, the Group has applied the following interpretations:

- Australian tax residency: The Group has applied current legislation and judicial precedent, including having regard to the Tax Commissioner's public guidance in Tax Ruling TR 2018/5.
- Foreign tax residency: The Group has applied current legislation, judicial precedent and practice in the determination of foreign tax residency.

The Directors of the Company declare that:

1. The Financial Statements and notes as set out on pages 24 to 65 are in accordance with the Corporations Act 2001 and:
 - (a) Comply with Accounting Standards, which, as stated in accounting policy note 2 to the financial statements, constitutes explicit and unreserved compliance with International Financial Reporting Standards (IFRS); and
 - (b) Give a true and fair view of the financial position as at 31 December 2024 and of the performance for the year ended on that date of the Company and Consolidated Group.
2. The Chief Executive Officer/Managing Director and Chief Financial Officer have each declared that:
 - (a) The financial records of the Consolidated Group for the financial year have been properly maintained in accordance with section 286 of the Corporations Act 2001;
 - (b) The financial statements and notes for the financial year comply with Accounting Standards; and
 - (c) The financial statements and notes for the financial year give a true and fair view.
3. In the Directors' opinion there are reasonable grounds to believe that the Consolidated Group will be able to pay its debts as and when they become due and payable.
4. In the Directors' opinion, the consolidated entity disclosure statement required by subsection 295(3A) of the Corporations Act 2001, is true and correct.

This declaration is made in accordance with a resolution of the Board of Directors.



Andrew O'Keefe
Managing Director
24 March 2025

Independent Auditor's Report to the Members of Vita Life Sciences Limited

Report on the Audit of the Financial Report

Opinion

We have audited the financial report of Vita Life Sciences Limited (the Company and its subsidiaries (the Group)), which comprises the consolidated statement of financial position as at 31 December 2024, the consolidated statement of profit or loss and other comprehensive income, consolidated statement of changes in equity and consolidated statement of cash flows for the year then ended, and notes to the financial statements, including material accounting policy information, the consolidated entity disclosure statement and the directors' declaration.

In our opinion, the accompanying financial report of the Group is in accordance with the Corporations Act 2001, including:

- i) giving a true and fair view of the Group's financial position as at 31 December 2024 and of its financial performance for the year then ended; and
- ii) complying with Australian Accounting Standards and the Corporations Regulations 2001.

Basis for opinion

We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those standards are further described in the 'auditor's responsibilities for the audit of the financial report' section of our report. We are independent of the Group in accordance with the Corporations Act 2001 and the ethical requirements of the Accounting Professional & Ethical Standards Board's APES 110 *Code of Ethics for Professional Accountants (including Independence Standards)* (the Code) that are relevant to our audit of the financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We confirm that the independence declaration required by the Corporations Act 2001, which has been given to the directors of the Company, would be in the same terms if given to the directors as at the time of this auditor's report.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key audit matters

Key audit matters are those matters that, in our professional judgement, were of most significance in our audit of the financial report of the current period. These matters were addressed in the context of our audit of the financial report as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

Key audit matter	How our audit addressed the key audit matter
<p>Revenue recognition (\$79,505,000)</p> <p>Refer to note 2(p) in the financial report.</p> <p>Revenue is an important measure by which to assess the performance of the Group.</p> <p>The measurement of revenue from contracts with customers is affected by a number of management's estimates and judgements including volume discounts, marketing rebates, and sales returns; particularly relating to the Group's Malaysian operations.</p> <p>Revenue recognition is considered a key audit matter as it is the most significant balance in the Group's statement of comprehensive income, is the key driver to the Group's operations, and is affected by management judgement and estimation in the measurement of contract liabilities.</p>	<p>Our procedures included, amongst others:</p> <ul style="list-style-type: none"> ▪ Assessment of the implementation and design of relevant internal controls in relation to revenue transactions by performing walkthroughs on a sample of revenue transactions to identify potential internal control deficiencies; ▪ Performance of revenue and gross margin analysis at a channel and product level to determine whether trends are aligned to expectations and market activity; ▪ Testing the occurrence and valuation of sales by agreeing a sample of transactions to the source and initiating documentation; ▪ Providing instructions and reviewing the audit work papers of the component auditor in Malaysia including reviewing management assumptions relating to volume discounts, marketing rebates and historical return values in order to assess management's estimate of the transaction price and the value of contract liabilities; ▪ Consideration of the quantum of claims and sales returns during the current and previous years and other factors to assess the reasonableness of management's estimates; and ▪ Performing cut-off testing on sales transactions for cut-off and completeness.

Other information

The directors are responsible for the other information. The other information comprises the information in Vita Life Sciences Limited's annual report for the year ended 31 December 2024, but does not include the financial report and the auditor's report thereon. Our opinion on the financial report does not cover the other information and we do not express any form of assurance conclusion thereon. In connection with our audit of the financial report, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial report or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of the other information we are required to report that fact. We have nothing to report in this regard.

Directors' responsibility for the financial report

The directors of the Company are responsible for the preparation of:

- a) the financial report (other than the consolidated entity disclosure statement) that gives a true and fair view in accordance with Australian Accounting Standards and the Corporations Act 2001; and
- b) the consolidated entity disclosure statement that is true and correct in accordance with the Corporations Act 2001, and

for such internal control as the directors determine is necessary to enable the preparation of:

- i) the financial report (other than the consolidated entity disclosure statement) that gives a true and fair view and is free from material misstatement, whether due to fraud or error; and
- ii) the consolidated entity disclosure statement that is true and correct and is free of misstatement, whether due to fraud or error.

In preparing the financial report, the directors are responsible for assessing the Group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the Group or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibility for the audit of the financial report

Our objectives are to obtain reasonable assurance about whether the financial report as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Australian Auditing Standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this financial report.

A further description of our responsibilities for the audit of the financial report is located at The Australian Auditing and Assurance Standards Board website at: www.auasb.gov.au/admin/file/content102/c3/ar1_2020.pdf. This description forms part of our auditor's report.

Report on the Remuneration Report

Opinion on the Remuneration Report

We have audited the Remuneration Report included in pages 14 to 20 of the directors' Report for the year ended 31 December 2024.

In our opinion, the Remuneration Report of Vita Life Sciences Limited for the year ended 31 December 2024, complies with section 300A of the Corporations Act 2001.

Responsibilities

The directors of the Company are responsible for the preparation and presentation of the Remuneration Report in accordance with section 300A of the Corporations Act 2001. Our responsibility is to express an



opinion on the Remuneration Report, based on our audit conducted in accordance with Australian Auditing Standards.

A handwritten signature in blue ink that reads "Nexia".

Nexia Sydney Audit Pty Ltd

A handwritten signature in blue ink that reads "Stephen Fisher".

Stephen Fisher
Director

Dated: 24 March 2025
Sydney

For personal use only

THE FOLLOWING INFORMATION IS CURRENT AS AT 28 FEBRUARY 2025

A. SUBSTANTIAL SHAREHOLDERS

The following have advised that they have a relevant interest in the capital of Vita Life Sciences Limited. The holding of a relevant interest does not infer beneficial ownership. Where two or more parties have a relevant interest in the same shares, those shares have been included for each party.

Shareholder	No. of ordinary	Percentage held of issued ordinary capital
CHEMICAL OVERSEAS LIMITED	8,551,439	15.1%
VICKY TEOH	8,435,693	14.9%
BARINGS ACCEPTANCE LIMITED	7,371,832	13.0%
ANGLO AUSTRALIAN CHRISTIAN & CHARITABLE FUND	6,276,040	11.1%
TIE LIM SUNG	4,040,366	7.2%
SG HISCOCK & COMPANY LIMITED	2,870,584	5.1%

B. DISTRIBUTION OF EQUITY SECURITY HOLDERS

(i) Analysis of number of equity security holders by size of holding as at 28 February 2025:

Category	Ordinary shareholders
1 - 1,000	234
1,001 - 5,000	304
5,001 - 10,000	111
10,001 - 100,000	192
100,001 and over	45
	886

(ii) There were 64 holders of less than a marketable parcel of ordinary shares.

THE FOLLOWING INFORMATION IS CURRENT AS AT 28 FEBRUARY 2025

C. EQUITY SECURITY HOLDERS

Twenty largest equity security holders	Number held	Percentage of shares issued
CHEMICAL OVERSEAS LIMITED	8,551,439	15.1%
VICKY TEOH	8,435,693	14.9%
BARINGS ACCEPTANCE LIMITED	7,371,832	13.0%
ANGLO AUSTRALIAN CHRISTIAN & CHARITABLE FUND	6,276,040	11.1%
TIE LIM SUNG	4,040,366	7.2%
HSBC CUSTODY NOMINEES (AUSTRALIA) LIMITED	3,231,464	5.7%
SOUTH SEAS HOLDINGS PTY LTD	1,345,430	2.4%
J P MORGAN NOMINEES AUSTRALIA PTY LTD	948,950	1.7%
ANDREW WARREN O'KEEFE	890,000	1.6%
B F A PTY LTD	837,591	1.5%
TAN TEIK WEI	811,607	1.4%
K S BEH	524,890	0.9%
CITICORP NOMINEES PTY LTD	440,647	0.8%
UBS NOMINEES PTY LTD	431,293	0.8%
PACOM SDN BHD	418,146	0.7%
REDBROOK NOMINEES PTY LTD	363,375	0.6%
CHIN L KHOO	353,348	0.6%
FINCLEAR PTY LTD	350,238	0.6%
GLIOCAS INVESTMENTS PTY LTD	329,295	0.6%
SHAUN RUTHERFORD	322,950	0.6%

D. VOTING RIGHTS

The Company's Constitution details the voting rights of members and states that every member, present in person or by proxy, shall have one vote for every ordinary share registered in his or her name.

Board of Directors**Henry Townsing**

Chairman
Non-Executive Director

Andrew O'Keefe

Managing Director

Peter Osborne

Non-Executive Director

Jack Teoh

Non-Executive Director

Company Secretary**Chin L Khoo**

Company Secretary
Chief Financial Officer

Registered Office**Australian Head Office**

Unit 1/ 102,
Bath Road, Kirrawee
NSW 2232
T: 61 2 9545 2633
F: 61 2 9545 1311

Asian Regional Office

No. 23, Jalan Jurunilai U1/20
Hicom Glenmarie Industrial Park
Seksyen U1
40150 Shah Alam
Selangor Darul Ehsan
Malaysia
T: 60 3 5569 6323
F: 60 3 5569 2393

Securities Exchange Listing

The ordinary shares of Vita Life Sciences Limited are listed on the Australian Securities Exchange Ltd

(code: VLS)

Auditor

Nexia Sydney Audit Pty Limited
Level 22, 2 Market Street
Sydney NSW 2000

Banker

National Australia Bank Limited
Westpac Banking Corporation

Solicitor

K&L Gates LLP
Level 25, 525 Collins St
Melbourne VIC 3000

Share Registry

Automic
Level 5, 126 Phillip Street
Sydney NSW 2000
T: 1300 288 664
T: 61 2 8072 1400

Change of Address

Shareholders who have changed address should advise our share registry in writing.

Annual Report Mailing

Shareholders who do not want the annual report or who are receiving more than one copy should advise the share registry in writing.

Vita Life Sciences Website

Vita Life Sciences has a website containing information about the Company, its Business and Products.

www.vitalifesciences.com

Corporate Governance Statement

<https://vitalifesciences.com/investor-centre/#corporate-governance>

For personal use only



VITA LIFE SCIENCES

Vita Life Sciences Limited

ACN 003 190 421
ABN 35 003 190 421

enquiries@vitalifesciences.com
vitalifesciences.com

Registered Office Australian Head Office

Unit 1/102 Bath Road
Kirrawee NSW 2232
Australia
T: 61 2 9545 2633
F: 61 2 9545 1311

Asian Regional Office

No. 23, Jalan Jurunilai U1/20
Hicom Glenmarie Industrial Park
Seksyen U1
40150 Shah Alam
Selangor Darul Ehsan
Malaysia
T: 60 3 5569 6323
F: 60 3 5569 2393